fenofibrate has been researched along with Hypertriglyceridemia in 167 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with NASH with hypertriglyceridemia treated with CILO and FIR, fenofibrate was safe and effectively mitigated increases in triglycerides associated with acetyl-CoA carboxylase inhibition." | 9.69 | Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. ( Bhandari, BR; Chuang, JC; Chung, C; Ding, D; Harting, E; Huss, RS; Kohli, A; Lawitz, EJ; Loomba, R; Myers, RP; Ruane, PJ, 2023) |
| " Plasma from overweight patients with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, participating in a randomized placebo-controlled study investigating the effects of 12 weeks treatment with fenofibrate or omega-3 free carboxylic acids (OM-3CA) (200 mg or 4 g per day, respectively), were analyzed for eicosanoids and related PUFA species, N-acylethanolamines (NAE) and ceramides." | 9.41 | Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease. ( Camacho-Muñoz, D; Kiezel-Tsugunova, M; Kiss, O; Lind, L; Nicolaou, A; Oscarsson, J; Ryaboshapkina, M; Sundén, M; Uddin, M, 2021) |
| " In humans, fenofibrate is used to control hypertriglyceridemia." | 9.41 | Fenofibrate treatment for severe hypertriglyceridemia in dogs. ( Blatter, MFC; Castillo, VA; Miceli, DD; Pignataro, OP; Vidal, VP, 2021) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 9.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| "Fenofibrate, a peroxisome proliferator-activated receptor-α (PPARα) agonist, is used to treat patients with hypercholesterolemia and hypertriglyceridemia in order to reduce the risk of development of the atherosclerotic cardiovascular disease." | 9.30 | Effect of fenofibrate on serum nitric oxide levels in patients with hypertriglyceridemia. ( Ayral, PA; Çiçek, ÖF; Esenboga, K; Gürlek, A; Oktay, AA, 2019) |
| " Fifty patients with hypertriglyceridemia in each group were given placebo, n-3 FA 2g+fenofibrate 160mg (combination), or fenofibrate 160mg, respectively daily for 2months." | 9.22 | Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, Y; Oh, PC; Sakuma, I; Shin, EK, 2016) |
| "Omega-3 fatty acids and fenofibrate are both used to treat patients with hypertriglyceridemia." | 9.16 | Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Quon, MJ; Sakuma, I; Shin, EK; Shin, KC, 2012) |
| "Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients." | 9.15 | Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, Y; Lee, YH; Lim, S; Quon, MJ; Sakuma, I; Shin, EK, 2011) |
| "8 mmol/L (500 mg/dL)) and ≥2 Adult Treatment Panel III criteria of the metabolic syndrome were randomized to daily fenofibrate (160 mg/d) or placebo for 12 weeks in a double-blind controlled clinical trial." | 9.14 | Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy. ( Helenowski, IB; Rosenson, RS; Tangney, CC, 2010) |
| "Fish oil was safe when administered alone or combined with fenofibrate and significantly reduced TG levels in HIV-infected subjects with hypertriglyceridemia." | 9.13 | Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. ( Aberg, JA; Acosta, EP; Benson, CA; Charles, S; Connick, E; Fichtenbaum, CJ; Gerber, JG; Hogg, E; Kitch, DW; Kojic, EM; Wohl, D; Zackin, RA, 2008) |
| " Therefore, the objective of this 2-group parallel study was to examine the differential effects of a 6-week treatment with atorvastatin or fenofibrate on in vivo kinetics of apo B-48 and B-100 in men with type 2 diabetes mellitus with marked hypertriglyceridemia." | 9.13 | Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. ( Bergeron, J; Couture, P; Deshaies, Y; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| "To examine the effects of fenofibrate (160mg/d) therapy on fasting and postprandial cytokine production in subjects with metabolic syndrome and hypertriglyceridemia." | 9.13 | Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. ( Helenowski, IB; Huskin, AL; Rademaker, AW; Rosenson, RS; Wolff, DA, 2008) |
| " The objective of this 2-group parallel study was to investigate the differential effects of a 6-week treatment with either atorvastatin 20 mg/d alone (n = 19) or micronized fenofibrate 200 mg/d alone (n = 19) on inflammation, cell adhesion, and oxidation markers in type 2 diabetes mellitus subjects with marked hypertriglyceridemia." | 9.13 | Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. ( Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| "Among hypertriglyceridemic subjects with the metabolic syndrome, fenofibrate therapy reduced Lp-PLA2 mass, and these changes were associated with fewer small LDL-Ps." | 9.13 | Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. ( Rosenson, RS, 2008) |
| "In the present study, 45 subjects with hypertriglyceridemia were recruited to receive treatment with fenofibrate (200 mg/d)." | 9.12 | Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia. ( Chen, MF; Li, YJ; Luo, BL; Xia, X; Yang, TL, 2006) |
| "The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome." | 9.12 | Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. ( Helenowski, IB; Huskin, AL; Rademaker, AW; Rosenson, RS; Wolff, DA, 2007) |
| "We investigated the effects of fenofibrate, peroxisome proliferator-activated receptors (PPARs) agonist, on endothelial function in patients with hypertriglyceridemia." | 9.11 | Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. ( Cheon Lee, K; Hwan Han, S; Kon Koh, K; Kyu Jin, D; Kyun Shin, E; Sakuma, I; Sik Kim, H; Yeal Ahn, J, 2004) |
| "Improvement in endothelial function is predicted to improve insulin sensitivity, and this may be one mechanism by which fenofibrate decreases the incidence of coronary heart disease." | 9.11 | Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Quon, MJ; Shin, EK; Yeal Ahn, J, 2005) |
| "To describe the effect of Coenzyme Q10 (CoQ10) (added to either a fibrate, or polyunsaturated fatty acids (PUFA) or association of both) in patients affected by massive hypertriglyceridemia (MHTG) resistant to fibrates and PUFA." | 9.11 | Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. ( Cicero, AF; Derosa, G; Gaddi, A; Laghi, L; Miconi, A; Nascetti, S, 2005) |
| "The aim of this study was to assess the food-related efficacy of a new formulation of micronized fenofibrate coated on inert microgranules (FF-muG) for the treatment of hypertriglyceridemia in patients exhibiting the metabolic syndrome." | 9.11 | Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. ( Bays, H; Davidson, MH; Doyle, R; Rhyne, J; Rotenberg, K; Stein, E, 2005) |
| "These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X." | 9.09 | Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. ( Blane, G; Idzior-Walus, B; Kawalec, E; Rostworowski, W; Sieradzki, J; Wójcik, J; Zarnecki, A; Zdzienicka, A, 2000) |
| " We studied 23 patients with elevated plasma triglycerides to evaluate the influence of fish oil and fenofibrate therapy on hemorrheological parameters (15 patients with familial hypertriglyceridemia [FHTG] and eight with familial dysbetalipoproteinemia [FDL])." | 9.08 | Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia. ( Otto, C; Richter, WO; Ritter, MM; Schwandt, P; Soennichsen, AC, 1996) |
| "A patient with hypothyroidism who presented with rhabdomyolysis during fenofibrate monotherapy for hypertriglyceridemia was reported." | 8.98 | Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review. ( Wang, D; Wang, Y, 2018) |
| "We report a case of rhabdomyolysis and ARF due to fenofibrate monotherapy in a 68-year-old female with post-pancreatitis diabetes mellitus and review reported cases of rhabdomyolysis correlated with fibrates monotherapy." | 7.96 | Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature. ( Cheng, Q; Li, D; Zhou, J, 2020) |
| "Bexarotene is an oral retinoid approved for treating cutaneous T-cell lymphoma (CTCL) in patients resistant to first-line systemic treatment." | 7.85 | Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. ( Bardés, I; Cabello, I; Corbella, X; Pintó, X; Servitje, O, 2017) |
| " We investigated the effect of fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, on RANTES in type 2 diabetes mellitus (T2DM) patients with hypertriglyceridemia." | 7.83 | PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. ( Feng, X; Gao, X; Jia, Y; Wang, G; Xu, Y; Zhang, H, 2016) |
| "Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) α ligand that has been widely used as a lipid-lowering agent in the treatment of hypertriglyceridemia." | 7.80 | ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesity. ( Aslibekyan, S; Fourcade, S; Graf, GA; Liang, S; Liu, J; Liu, X; Pujol, A; Schlüter, A, 2014) |
| "Fifty-eight patients with hypertriglyceridemia were divided into two groups: control (no treatment; n = 23) and fenofibrate treatment (n = 35), 200 mg/d, for 6 months." | 7.79 | Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia. ( Chen, AF; Feng, X; Hao, Y; He, L; Hong, T; Li, F; Liu, J; Mao, J; Wang, G; Wang, X; Yu, J, 2013) |
| "To describe a successful pregnancy in a patient who used fenofibrate during the first trimester." | 7.78 | Use of fenofibrate during the first trimester of unplanned pregnancy in a patient with hypertriglyceridemia. ( Aytemir, K; Canpolat, U; Sahiner, L; Sunman, H, 2012) |
| "Fenofibrate was used safely and successfully during pregnancy in this case of hypertriglyceridemia-associated pancreatitis refractory to conservative measures." | 7.77 | Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate. ( Lorenz, RP; Smith, JM; Whitten, AE, 2011) |
| " The hypertriglyceridemia induced by bifendate was ameliorated by fenofibrate but not inositol nicotinate treatment in mice." | 7.73 | High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: animal models of acute hypertriglyceridemia. ( Dong, H; Feng, XD; Geng, W; Han, YF; Ko, KM; Li, N; Pan, SY; Yang, R, 2006) |
| "To investigate the effect of micronized fenofibrate on vascular endothelial function in patients with hypertriglyceridemia." | 7.72 | Effect of micronized fenofibrate on vascular endothelial function in patients with hypertriglyceridemia. ( Cheng, B; Dai, G; Feng, Z; Huang, Y; Li, J; Lu, C; Nie, F; Wang, Q, 2003) |
| "To investigate the effect of transcription-modulating drugs, fenofibrate and isotretinoin, on metabolic profile, insulin sensitivity of adipose and muscle tissues and gene expression in a genetic model of insulin resistance syndrome, polydactylous rat strain (PD/Cub)." | 7.72 | Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. ( Kazdova, L; Kren, V; Krenova, D; Seda, O; Sedova, L, 2004) |
| "Our previous study demonstrated that fenofibrate improves both lipid metabolism and obesity, in part through hepatic peroxisome proliferator-activated receptor alpha (PPARalpha) activation, in female ovariectomized, but not in sham-operated, low-density lipoprotein receptor-null (LDLR-null) mice." | 7.72 | Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice. ( Ahn, J; Han, M; Jeong, S; Kim, M; Kim, TW; Lee, H; Nam, KH; Oh, GT; Shin, C; Song, YH; Yoon, M, 2004) |
| "To determine the effectiveness of fenofibrate in treating hypertriglyceridemia associated with highly active antiretroviral therapy-associated HIV lipodystrophy syndrome (HLS)." | 7.72 | Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. ( Balasubramanyam, A; D'Amico, S; Maldonado, M; Rao, A, 2004) |
| " Safety was evaluated based on data collected for adverse events (AEs), physical and electrocardiographic examinations, vital sign measurements, and clinical laboratory tests." | 6.75 | Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. ( Carlson, DM; Gold, A; Jones, PH; Kelly, MT; McKenney, JM; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA, 2010) |
| "Niacin was more effective at lowering LDL-C, Lp (a), and hs-CRP." | 6.75 | Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. ( Cho, SY; Chung, N; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Park, S; Shim, WH; Wi, J, 2010) |
| "Fenofibrate treatment significantly lowered T-cho, triglyceride, and LDL-C levels." | 6.73 | Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. ( Koide, J; Nakanishi, S; Nakashima, R; Oki, K; Yamane, K, 2007) |
| "In patients with NASH with hypertriglyceridemia treated with CILO and FIR, fenofibrate was safe and effectively mitigated increases in triglycerides associated with acetyl-CoA carboxylase inhibition." | 5.69 | Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. ( Bhandari, BR; Chuang, JC; Chung, C; Ding, D; Harting, E; Huss, RS; Kohli, A; Lawitz, EJ; Loomba, R; Myers, RP; Ruane, PJ, 2023) |
| "Saroglitazar, being a dual PPAR-α/γ agonist, has shown beneficial effect in diabetic dyslipidemia and hypertriglyceridemia." | 5.51 | Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial. ( Cruz-López, P; González, JG; Parmar, D; Rodriguez-Gutierrez, R; Shaikh, F, 2022) |
| " Plasma from overweight patients with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, participating in a randomized placebo-controlled study investigating the effects of 12 weeks treatment with fenofibrate or omega-3 free carboxylic acids (OM-3CA) (200 mg or 4 g per day, respectively), were analyzed for eicosanoids and related PUFA species, N-acylethanolamines (NAE) and ceramides." | 5.41 | Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease. ( Camacho-Muñoz, D; Kiezel-Tsugunova, M; Kiss, O; Lind, L; Nicolaou, A; Oscarsson, J; Ryaboshapkina, M; Sundén, M; Uddin, M, 2021) |
| " In humans, fenofibrate is used to control hypertriglyceridemia." | 5.41 | Fenofibrate treatment for severe hypertriglyceridemia in dogs. ( Blatter, MFC; Castillo, VA; Miceli, DD; Pignataro, OP; Vidal, VP, 2021) |
| "Fenofibrate (160 mg/d) was added." | 5.40 | Fenofibrate increases serum creatinine in a patient with familial nephropathy associated to hyperuricemia. ( Beltrán, LM; Puig, JG; Salgueiro, G; Torres, RJ, 2014) |
| "Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 5.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| "Fenofibrate treatment markedly suppressed the postprandial TG response in CD36KO along with decreased apoB-48 levels in plasma." | 5.36 | Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice. ( Inagaki, M; Ishigami, M; Kawase, R; Komuro, I; Masuda, D; Nakagawa-Toyama, Y; Nakaoka, H; Nakatani, K; Nishida, M; Ohama, T; Sandoval, JC; Tochino, Y; Tsubakio-Yamamoto, K; Yamashita, S; Yuasa-Kawase, M, 2010) |
| "This study was to research the efficacy of fenofibrate in the treatment of microalbuminuria in the patients with type 2 diabetes mellitus (T2DM) and hypertriglyceridemia." | 5.34 | Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia. ( Liu, J; Sun, X; Wang, G, 2020) |
| " Fifty patients with hypertriglyceridemia in each group were given placebo, n-3 FA 2g+fenofibrate 160mg (combination), or fenofibrate 160mg, respectively daily for 2months." | 5.22 | Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, Y; Oh, PC; Sakuma, I; Shin, EK, 2016) |
| "Omega-3 fatty acids and fenofibrate are both used to treat patients with hypertriglyceridemia." | 5.16 | Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Quon, MJ; Sakuma, I; Shin, EK; Shin, KC, 2012) |
| "Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients." | 5.15 | Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Lee, Y; Lee, YH; Lim, S; Quon, MJ; Sakuma, I; Shin, EK, 2011) |
| "The objective of this study was to evaluate the long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients at goal for low-density lipoprotein cholesterol (LDL-C) but with persistent hypertriglyceridemia." | 5.15 | Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. ( Ballantyne, CM; Jones, PH; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Thakker, KM, 2011) |
| "During the 8-week double-blind phase in subjects receiving fenofibrate, the addition of P-OM3 (versus placebo) did not significantly change median (minimum, maximum) body weight (P-OM3 = 0 [-4." | 5.14 | The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels. ( Bays, HE; Doyle, RT; Maki, KC; Stein, E, 2009) |
| "8 mmol/L (500 mg/dL)) and ≥2 Adult Treatment Panel III criteria of the metabolic syndrome were randomized to daily fenofibrate (160 mg/d) or placebo for 12 weeks in a double-blind controlled clinical trial." | 5.14 | Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy. ( Helenowski, IB; Rosenson, RS; Tangney, CC, 2010) |
| "Fish oil was safe when administered alone or combined with fenofibrate and significantly reduced TG levels in HIV-infected subjects with hypertriglyceridemia." | 5.13 | Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. ( Aberg, JA; Acosta, EP; Benson, CA; Charles, S; Connick, E; Fichtenbaum, CJ; Gerber, JG; Hogg, E; Kitch, DW; Kojic, EM; Wohl, D; Zackin, RA, 2008) |
| " Therefore, the objective of this 2-group parallel study was to examine the differential effects of a 6-week treatment with atorvastatin or fenofibrate on in vivo kinetics of apo B-48 and B-100 in men with type 2 diabetes mellitus with marked hypertriglyceridemia." | 5.13 | Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. ( Bergeron, J; Couture, P; Deshaies, Y; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| "To examine the effects of fenofibrate (160mg/d) therapy on fasting and postprandial cytokine production in subjects with metabolic syndrome and hypertriglyceridemia." | 5.13 | Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. ( Helenowski, IB; Huskin, AL; Rademaker, AW; Rosenson, RS; Wolff, DA, 2008) |
| " The objective of this 2-group parallel study was to investigate the differential effects of a 6-week treatment with either atorvastatin 20 mg/d alone (n = 19) or micronized fenofibrate 200 mg/d alone (n = 19) on inflammation, cell adhesion, and oxidation markers in type 2 diabetes mellitus subjects with marked hypertriglyceridemia." | 5.13 | Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. ( Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| "Among hypertriglyceridemic subjects with the metabolic syndrome, fenofibrate therapy reduced Lp-PLA2 mass, and these changes were associated with fewer small LDL-Ps." | 5.13 | Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. ( Rosenson, RS, 2008) |
| "In the present study, 45 subjects with hypertriglyceridemia were recruited to receive treatment with fenofibrate (200 mg/d)." | 5.12 | Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia. ( Chen, MF; Li, YJ; Luo, BL; Xia, X; Yang, TL, 2006) |
| "We investigated the effects of fenofibrate on C-reactive protein (CRP) levels in patients with hypertriglyceridemia." | 5.12 | Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients. ( Kim, CJ, 2006) |
| "The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome." | 5.12 | Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. ( Helenowski, IB; Huskin, AL; Rademaker, AW; Rosenson, RS; Wolff, DA, 2007) |
| "Fenofibrate therapy improves the atherogenic lipid profile in HIV-positive adults with hypertriglyceridemia." | 5.11 | Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. ( Badiou, S; Baillat, V; Cristol, JP; Dupuy, AM; Merle De Boever, C; Reynes, J, 2004) |
| "We investigated the effects of fenofibrate, peroxisome proliferator-activated receptors (PPARs) agonist, on endothelial function in patients with hypertriglyceridemia." | 5.11 | Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. ( Cheon Lee, K; Hwan Han, S; Kon Koh, K; Kyu Jin, D; Kyun Shin, E; Sakuma, I; Sik Kim, H; Yeal Ahn, J, 2004) |
| "Improvement in endothelial function is predicted to improve insulin sensitivity, and this may be one mechanism by which fenofibrate decreases the incidence of coronary heart disease." | 5.11 | Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. ( Han, SH; Koh, KK; Quon, MJ; Shin, EK; Yeal Ahn, J, 2005) |
| "To describe the effect of Coenzyme Q10 (CoQ10) (added to either a fibrate, or polyunsaturated fatty acids (PUFA) or association of both) in patients affected by massive hypertriglyceridemia (MHTG) resistant to fibrates and PUFA." | 5.11 | Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. ( Cicero, AF; Derosa, G; Gaddi, A; Laghi, L; Miconi, A; Nascetti, S, 2005) |
| "The aim of this study was to assess the food-related efficacy of a new formulation of micronized fenofibrate coated on inert microgranules (FF-muG) for the treatment of hypertriglyceridemia in patients exhibiting the metabolic syndrome." | 5.11 | Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. ( Bays, H; Davidson, MH; Doyle, R; Rhyne, J; Rotenberg, K; Stein, E, 2005) |
| "A combination of fenofibrate or losartan with anti-hyperuricaemic agents is a good option for the treatment of gout patients with hypertriglyceridaemia and/or hypertension, though the additional hypouricaemic effect may be modest." | 5.10 | Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. ( Fukuchi, M; Ka, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2003) |
| "These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X." | 5.09 | Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. ( Blane, G; Idzior-Walus, B; Kawalec, E; Rostworowski, W; Sieradzki, J; Wójcik, J; Zarnecki, A; Zdzienicka, A, 2000) |
| " We studied 23 patients with elevated plasma triglycerides to evaluate the influence of fish oil and fenofibrate therapy on hemorrheological parameters (15 patients with familial hypertriglyceridemia [FHTG] and eight with familial dysbetalipoproteinemia [FDL])." | 5.08 | Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia. ( Otto, C; Richter, WO; Ritter, MM; Schwandt, P; Soennichsen, AC, 1996) |
| "A patient with hypothyroidism who presented with rhabdomyolysis during fenofibrate monotherapy for hypertriglyceridemia was reported." | 4.98 | Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review. ( Wang, D; Wang, Y, 2018) |
| "The acute severe DILI occurred within only 4 days after fenofibrate initial treatment for hypertriglyceridemia." | 3.96 | Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database. ( Chen, L; Liu, S; Ma, S; Sun, H; Wang, Q; Yang, P, 2020) |
| "We report a case of rhabdomyolysis and ARF due to fenofibrate monotherapy in a 68-year-old female with post-pancreatitis diabetes mellitus and review reported cases of rhabdomyolysis correlated with fibrates monotherapy." | 3.96 | Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature. ( Cheng, Q; Li, D; Zhou, J, 2020) |
| "Bexarotene is an oral retinoid approved for treating cutaneous T-cell lymphoma (CTCL) in patients resistant to first-line systemic treatment." | 3.85 | Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. ( Bardés, I; Cabello, I; Corbella, X; Pintó, X; Servitje, O, 2017) |
| " We investigated the effect of fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, on RANTES in type 2 diabetes mellitus (T2DM) patients with hypertriglyceridemia." | 3.83 | PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia. ( Feng, X; Gao, X; Jia, Y; Wang, G; Xu, Y; Zhang, H, 2016) |
| "Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) α ligand that has been widely used as a lipid-lowering agent in the treatment of hypertriglyceridemia." | 3.80 | ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesity. ( Aslibekyan, S; Fourcade, S; Graf, GA; Liang, S; Liu, J; Liu, X; Pujol, A; Schlüter, A, 2014) |
| "Fifty-eight patients with hypertriglyceridemia were divided into two groups: control (no treatment; n = 23) and fenofibrate treatment (n = 35), 200 mg/d, for 6 months." | 3.79 | Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia. ( Chen, AF; Feng, X; Hao, Y; He, L; Hong, T; Li, F; Liu, J; Mao, J; Wang, G; Wang, X; Yu, J, 2013) |
| "Fenofibrate was used safely and successfully during pregnancy in this case of hypertriglyceridemia-associated pancreatitis refractory to conservative measures." | 3.77 | Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate. ( Lorenz, RP; Smith, JM; Whitten, AE, 2011) |
| "A 35-year-old woman had been treated for acne since the age of 22 years, as part of which she received two courses of oral isotretinoin." | 3.77 | [Multiple cutaneous osteomas of the face in a setting of chronic acne]. ( Celerier, P; Fenot, M; Maillard, H; Rivet, J; Sierra-Fortuny, S, 2011) |
| "2%) of participants used 1 of 3 prescription medications indicated to treat hypertriglyceridemia (ie, fenofibrate, gemfibrozil, or niacin); this percentage was 2." | 3.75 | Hypertriglyceridemia and its pharmacologic treatment among US adults. ( Ford, ES; Li, C; Mokdad, AH; Pearson, WS; Zhao, G, 2009) |
| " A cost-effectiveness study comparing fenofibrate, a fibrate agent, and atorvastatin was therefore conducted in hypertriglyceridemia patients." | 3.74 | Pharmacoeconomic analysis of hypertriglyceridemia treatment at medical institutions. ( Saegusa, Y; Shiragami, M; Takahashi, T; Takimoto, Y, 2008) |
| "Fenofibrate therapy was initiated for a 60-year old Hispanic man with stage 4 chronic kidney disease (CKD) for the treatment of hypertriglyceridemia." | 3.74 | Elevated serum creatinine levels associated with fenofibrate therapy. ( Anderson, J; Griego, J; McQuade, CR; Pai, AB, 2008) |
| " The hypertriglyceridemia induced by bifendate was ameliorated by fenofibrate but not inositol nicotinate treatment in mice." | 3.73 | High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: animal models of acute hypertriglyceridemia. ( Dong, H; Feng, XD; Geng, W; Han, YF; Ko, KM; Li, N; Pan, SY; Yang, R, 2006) |
| "To investigate the effect of transcription-modulating drugs, fenofibrate and isotretinoin, on metabolic profile, insulin sensitivity of adipose and muscle tissues and gene expression in a genetic model of insulin resistance syndrome, polydactylous rat strain (PD/Cub)." | 3.72 | Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome. ( Kazdova, L; Kren, V; Krenova, D; Seda, O; Sedova, L, 2004) |
| "Our previous study demonstrated that fenofibrate improves both lipid metabolism and obesity, in part through hepatic peroxisome proliferator-activated receptor alpha (PPARalpha) activation, in female ovariectomized, but not in sham-operated, low-density lipoprotein receptor-null (LDLR-null) mice." | 3.72 | Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice. ( Ahn, J; Han, M; Jeong, S; Kim, M; Kim, TW; Lee, H; Nam, KH; Oh, GT; Shin, C; Song, YH; Yoon, M, 2004) |
| "To determine the effectiveness of fenofibrate in treating hypertriglyceridemia associated with highly active antiretroviral therapy-associated HIV lipodystrophy syndrome (HLS)." | 3.72 | Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. ( Balasubramanyam, A; D'Amico, S; Maldonado, M; Rao, A, 2004) |
| "To verify the superiority of pemafibrate over placebo and the non-inferiority of pemafibrate to the maximum dose of fenofibrate for determining the percent change in fasting serum triglyceride (TG) levels and to investigate safety by assessing the incidence of adverse events (AEs) and adverse drug reactions (ADRs)." | 2.87 | Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. ( Arai, H; Araki, E; Ishibashi, S; Suganami, H; Yamashita, S; Yokote, K, 2018) |
| " Safety was evaluated based on data collected for adverse events (AEs), physical and electrocardiographic examinations, vital sign measurements, and clinical laboratory tests." | 2.75 | Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. ( Carlson, DM; Gold, A; Jones, PH; Kelly, MT; McKenney, JM; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA, 2010) |
| "Fenofibrate is a commonly used drug to treat hypertriglyceridemia, but response to fenofibrate varies considerably among individuals." | 2.75 | Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. ( Arnett, DK; Borecki, I; Chung, BH; Gao, G; Hopkins, PN; Lai, CQ; Ordovas, JM; Parnell, L; Wojczynski, MK, 2010) |
| "Niacin was more effective at lowering LDL-C, Lp (a), and hs-CRP." | 2.75 | Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. ( Cho, SY; Chung, N; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Park, S; Shim, WH; Wi, J, 2010) |
| "Treatment of severe hypertriglyceridemia is indicated to reduce the risk of pancreatitis in patients with triglyceride (TG) levels > or =500 mg/dL." | 2.74 | Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects. ( Bays, HE; Carter, R; Doyle, RT; Forker, AD; Maki, KC; Roth, EM; Stein, EA, 2009) |
| "Omega-3 ensures a protective effect on cardiac diseases, arthrosis, elasticity of vessels, prolong the bleeding time, improve the theology of the blood, protect the endothelium by atherosclerosis, low heart rate and blood pressure, reduce the risk for cardiac arrhythmya, etc." | 2.73 | Which dose of omega-3 fatty acids must be taken in different cases of hypertriglyceridemia? ( Dondoi, C; Mogoş, T, 2008) |
| "Fenofibrate treatment significantly lowered T-cho, triglyceride, and LDL-C levels." | 2.73 | Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. ( Koide, J; Nakanishi, S; Nakashima, R; Oki, K; Yamane, K, 2007) |
| "Fenofibrate is a marketed fibric acid derivative for lipid-lowering in patients with lipid disorders." | 2.72 | Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis. ( Chen, Y; Dong, Z; Ji, X; Li, C; Li, R; Lu, J; Zhang, J; Zhao, Y, 2021) |
| "Fenofibrate combined with candesartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy in hypertriglyceridemic hypertensive patients." | 2.72 | Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. ( Ahn, JY; Chung, WJ; Han, SH; Kim, JA; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2006) |
| "Hypertriglyceridemia is often associated with small dense low density lipoprotein (LDL), elevated remnants, and decreased high density lipoprotein (HDL)-cholesterol (C), which comprise the dyslipidemic triad." | 2.71 | Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study. ( Ikewaki, K; Kido, T; Mochizuki, S; Nakata, Y; Tohyama, J; Wakikawa, T, 2004) |
| "When Fenofibrate group was divided into two subgroups according to the degree of percentage change in lipoprotein(a) level, change in triglyceride level and alanine aminotransferase level were independent predictors by forward logistic regression analysis." | 2.71 | Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function. ( Kim, CJ; Ko, HS; Ryu, WS, 2005) |
| " This short-term study showed few adverse effects for both drugs." | 2.67 | Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. ( Bonnefous, F; Debbas, N; Farnier, M; Irvine, A, 1994) |
| "Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day)." | 2.61 | New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. ( Preston Mason, R, 2019) |
| "Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease." | 2.43 | Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006) |
| "Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism." | 2.42 | Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003) |
| "Diagnoses included diabetic ketosis, severe hypertriglyceridemia (>225 mmol/L [>20,000 mg/dl]), lipemia retinalis, and bilateral uveitis." | 1.91 | Successful multimodal treatment of extreme hypertriglyceridemia in a juvenile diabetic dog. ( Beatty, SSK; Cagle, LA; Ehrhardt, CM; Gilor, C; Guarino, AL; Londoño, LA; Specht, AJ; Stern, JK, 2023) |
| " We suggest that Pema may be an effective and safe treatment for hypertriglyceridemia in CKD patients." | 1.91 | Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study. ( Fukuda, H; Iwasaki, M; Koshida, T; Matsuzaki, K; Saito, M; Suzuki, H; Suzuki, Y; Takahara, H; Umezawa, Y, 2023) |
| "A fenofibrate was proposed but declined due to our patient's wish to breastfeed." | 1.72 | Hypertriglyceridaemia in pregnancy: an unexpected diagnosis and its management. ( Barclay, K; Kaplan, F; Koysombat, K; Padmagirison, R, 2022) |
| "Fenofibrate (Fb) is a known treatment for elevated triglyceride (TG) levels." | 1.48 | Detecting responses to treatment with fenofibrate in pedigrees. ( Bickeböller, H; Cantor, RM; Cherlin, S; Wang, MH, 2018) |
| "Fenofibrate (160 mg/d) was added." | 1.40 | Fenofibrate increases serum creatinine in a patient with familial nephropathy associated to hyperuricemia. ( Beltrán, LM; Puig, JG; Salgueiro, G; Torres, RJ, 2014) |
| "Hypertriglyceridemia is an important and under-diagnosed etiology of acute non-biliary pancreatitis." | 1.39 | An acute edematous pancreatitis case developed on the basis of hypertriglyceridemia. ( Aslan, T; Aykas, F; Erden, A; Karagoz, H; Karahan, S; Karaman, A; Mutlu, H; Uslu, E, 2013) |
| "Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors." | 1.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| "Fenofibrate treatment reduced high triglycerides in the fructose-fed HTG rat and subsequently restored the cardioprotective effect of IPC." | 1.39 | Fenofibrate attenuates impaired ischemic preconditioning-mediated cardioprotection in the fructose-fed hypertriglyceridemic rat heart. ( Babbar, L; Balakumar, P; Mahadevan, N, 2013) |
| "Berardinelli- Seip syndrome is an autosomal recessive disorder characterized by generalized lipoatrophy, extreme insulin resistance with dyslipidemia in childhood and development of diabetes in adolescence." | 1.38 | An unusual cause of delayed puberty: Berardinelli- Seip syndrome. ( Dhull, P; Kumar, KV; Patnaik, SK; Upreti, V, 2012) |
| "Fenofibrate treatment resulted in a 30." | 1.37 | Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants. ( Arnett, D; Hanson, NQ; Ordovas, JM; Steffen, BT; Straka, R; Tsai, AK; Tsai, MY; Zhou, X, 2011) |
| "Fenofibrate treatment markedly suppressed the postprandial TG response in CD36KO along with decreased apoB-48 levels in plasma." | 1.36 | Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice. ( Inagaki, M; Ishigami, M; Kawase, R; Komuro, I; Masuda, D; Nakagawa-Toyama, Y; Nakaoka, H; Nakatani, K; Nishida, M; Ohama, T; Sandoval, JC; Tochino, Y; Tsubakio-Yamamoto, K; Yamashita, S; Yuasa-Kawase, M, 2010) |
| "Hypertriglyceridemia is a risk factor for cardiovascular disease." | 1.35 | Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. ( Arnett, DK; Borecki, I; Corella, D; Guillen, M; Kai, CS; Kathiresan, S; Lai, CQ; Lopez-Miranda, J; Ordovas, JM; Orho-Melander, M; Parnell, LD; Perez-Jimenez, F; Perez-Martinez, P; Province, M; Shen, J; Straka, RJ; Tai, ES; Tsai, M; Tucker, KL; Yiannakouris, N, 2009) |
| "In a patient with diabetic ketoacidosis complicated by severe elevation of plasma triglyceride concentrations, treatment with low-level intravenous unfractionated heparin led to prompt reduction in plasma triglyceride concentration and may have prevented the development of hypertriglyceridemia-associated acute pancreatitis." | 1.35 | Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis. ( Cole, RP, 2009) |
| " The inadequate activity of fenofibrate over the 5 years of the FIELD study might be due to bioavailability problems previously noted with some slow release formulations." | 1.35 | Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer. ( Banfi, F; Falcioni, S; Mombelli, G; Sirtori, CR, 2009) |
| "Fenofibrate treatment normalized the plasma lipoprotein profile of patients with complete HL deficiency, as evidenced by significant reductions in the plasma concentration of cholesterol (-49%) and triglycerides (-82%) and a significant increase in low-density lipoprotein (LDL) size (251." | 1.33 | Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency. ( Badellino, KO; Cohn, JS; Couture, P; Lamarche, B; Marcil, M; Mauger, JF; Ruel, IL, 2005) |
| "Fenofibrate (0." | 1.33 | A novel experimental model of acute hypertriglyceridemia induced by schisandrin B. ( Dong, H; Han, YF; Ko, KM; Li, WY; Pan, SY; Zhao, XY, 2006) |
| "Fenofibrate is a new lipid-lowering agent for adults with very high triglyceride levels that was administered to two HIV-positive patients who were taking protease inhibitors and developed hypertriglyceridemia." | 1.31 | Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities. ( Bultemeier, NC; Cerveny, JD; Del Bene, VE; Lopes-Virella, MF; McWhorter, LS; Taylor, KB; Thomas, JC, 2000) |
| "Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist which regulates the transcription of genes encoding proteins involved in triglyceride (TG)-rich lipoproteins and lipoprotein lipase (LPL) metabolism." | 1.31 | Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients. ( Bossé, Y; Brisson, D; Gaudet, D; Hudson, TJ; Julien, P; Ledoux, K; Perron, P; St-Pierre, J; Vohl, MC, 2002) |
| "Treatment with fenofibrate significantly reduced the linoleic acid (18:2n-6) in PC and TAG plasma, CE and TG LDL, in a higher ratio of palmitoleic acid (16:1n-7) in CE LDL, oleic (18:1n-9) in PC LDL, in significant concentration of total monoenic FA in PC and CE LDL and to a significant increase of the concentration of myristic acid (14:0) in CE and myristic and stearic acids (18:0) in TAG LDL." | 1.31 | [Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia]. ( Konárková, M; Stípek, S; Tvrzická, E; Zák, A; Zeman, M, 2002) |
| "The purpose of this study was to investigate the effect of low high-density-lipoprotein (HDL) combined with hypertriglyceridemia in coronary artery disease (CAD) patients on prostaglandin I2 (PGI2) biological activity in relation to lipid regulating treatment." | 1.30 | Effect of low HDL combined with hypertriglyceridemia in coronary artery disease patients on PGI2 biological activity in relation to lipid regulating treatment. ( Dai, G; Feng, Z; Li, J; Wang, C; Wei, W; Yang, Y; Zhou, B, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.20) | 18.7374 |
| 1990's | 8 (4.79) | 18.2507 |
| 2000's | 76 (45.51) | 29.6817 |
| 2010's | 65 (38.92) | 24.3611 |
| 2020's | 16 (9.58) | 2.80 |
| Authors | Studies |
|---|---|
| Das, SK | 1 |
| Narasimha Rao Krovvidi, VL | 1 |
| Jagadheshan, H | 1 |
| Iqbal, J | 1 |
| Camacho-Muñoz, D | 1 |
| Kiezel-Tsugunova, M | 1 |
| Kiss, O | 1 |
| Uddin, M | 1 |
| Sundén, M | 1 |
| Ryaboshapkina, M | 1 |
| Lind, L | 1 |
| Oscarsson, J | 1 |
| Nicolaou, A | 1 |
| Lawitz, EJ | 1 |
| Bhandari, BR | 1 |
| Ruane, PJ | 1 |
| Kohli, A | 1 |
| Harting, E | 1 |
| Ding, D | 1 |
| Chuang, JC | 1 |
| Huss, RS | 1 |
| Chung, C | 1 |
| Myers, RP | 1 |
| Loomba, R | 1 |
| Rodriguez-Gutierrez, R | 1 |
| González, JG | 1 |
| Parmar, D | 1 |
| Shaikh, F | 1 |
| Cruz-López, P | 1 |
| Feng, L | 2 |
| Sun, Y | 1 |
| Liu, F | 1 |
| Wang, C | 3 |
| Zhang, C | 2 |
| Liu, J | 4 |
| Jiang, L | 2 |
| Grasser, LR | 1 |
| Saad, B | 1 |
| Bazzi, C | 1 |
| Wanna, C | 1 |
| Abu Suhaiban, H | 1 |
| Mammo, D | 1 |
| Jovanovic, T | 1 |
| Javanbakht, A | 1 |
| Miceli, DD | 2 |
| Guevara, JM | 1 |
| Ferraris, S | 1 |
| Pignataro, OP | 2 |
| Gallelli, MF | 1 |
| Ramadhan, ZR | 1 |
| Poerwoprajitno, AR | 1 |
| Cheong, S | 1 |
| Webster, RF | 1 |
| Kumar, PV | 1 |
| Cychy, S | 1 |
| Gloag, L | 1 |
| Benedetti, TM | 1 |
| Marjo, CE | 1 |
| Muhler, M | 1 |
| Wang, DW | 1 |
| Gooding, JJ | 1 |
| Schuhmann, W | 1 |
| Tilley, RD | 1 |
| Vijayakumar, A | 1 |
| Okesli-Armlovich, A | 1 |
| Wang, T | 1 |
| Olson, I | 1 |
| Seung, M | 1 |
| Kusam, S | 1 |
| Hollenback, D | 1 |
| Mahadevan, S | 1 |
| Marchand, B | 1 |
| Toteva, M | 1 |
| Breckenridge, DG | 1 |
| Trevaskis, JL | 1 |
| Bates, J | 1 |
| Barclay, K | 1 |
| Koysombat, K | 1 |
| Padmagirison, R | 1 |
| Kaplan, F | 1 |
| Guarino, AL | 1 |
| Cagle, LA | 1 |
| Ehrhardt, CM | 1 |
| Beatty, SSK | 1 |
| Stern, JK | 1 |
| Gilor, C | 1 |
| Specht, AJ | 1 |
| Londoño, LA | 1 |
| Iwasaki, M | 1 |
| Suzuki, H | 1 |
| Umezawa, Y | 1 |
| Koshida, T | 1 |
| Saito, M | 1 |
| Fukuda, H | 1 |
| Takahara, H | 1 |
| Matsuzaki, K | 1 |
| Suzuki, Y | 1 |
| Ma, S | 1 |
| Liu, S | 1 |
| Wang, Q | 2 |
| Chen, L | 1 |
| Yang, P | 1 |
| Sun, H | 1 |
| Blasco, M | 1 |
| Ascaso, JF | 1 |
| Sun, X | 1 |
| Wang, G | 3 |
| Imai, M | 1 |
| Yamamoto, H | 1 |
| Hashimoto, T | 1 |
| Koyama, H | 1 |
| Kihara, S | 1 |
| Zhou, J | 1 |
| Li, D | 1 |
| Cheng, Q | 1 |
| Kayıkçıoğlu, M | 1 |
| Shahbazova, S | 1 |
| İbrahimov, F | 1 |
| Can, LH | 1 |
| Vidal, VP | 1 |
| Blatter, MFC | 1 |
| Castillo, VA | 1 |
| Zhang, J | 1 |
| Ji, X | 1 |
| Dong, Z | 1 |
| Lu, J | 1 |
| Zhao, Y | 1 |
| Li, R | 1 |
| Li, C | 2 |
| Chen, Y | 1 |
| Sairyo, M | 1 |
| Kobayashi, T | 1 |
| Masuda, D | 2 |
| Kanno, K | 1 |
| Zhu, Y | 1 |
| Okada, T | 1 |
| Koseki, M | 1 |
| Ohama, T | 2 |
| Nishida, M | 2 |
| Sakata, Y | 1 |
| Yamashita, S | 3 |
| Krysiak, R | 1 |
| Szkróbka, W | 1 |
| Okopień, B | 1 |
| Cornejo-Uixeda, S | 1 |
| Escoin-Pérez, C | 1 |
| Hernandez-Lorente, E | 1 |
| Wang, D | 2 |
| Wang, Y | 2 |
| Arai, H | 1 |
| Yokote, K | 1 |
| Araki, E | 1 |
| Suganami, H | 1 |
| Ishibashi, S | 1 |
| Sarnowski, C | 2 |
| Lent, S | 2 |
| Dupuis, J | 2 |
| Xu, H | 1 |
| Wang, L | 1 |
| Wang, Z | 1 |
| Hivert, MF | 1 |
| Wei, R | 1 |
| Wu, Y | 1 |
| Auerbach, J | 1 |
| Howey, R | 1 |
| Justice, A | 1 |
| Li, L | 1 |
| Oualkacha, K | 1 |
| Sayols-Baixeras, S | 1 |
| Aslibekyan, SW | 1 |
| Cherlin, S | 1 |
| Wang, MH | 1 |
| Bickeböller, H | 1 |
| Cantor, RM | 1 |
| Preston Mason, R | 1 |
| Sahebkar, A | 1 |
| Simental-Mendía, LE | 1 |
| Katsiki, N | 1 |
| Reiner, Ž | 1 |
| Banach, M | 1 |
| Pirro, M | 2 |
| Atkin, SL | 1 |
| Scheen, AJ | 1 |
| Wallemacq, C | 1 |
| De Flines, J | 1 |
| Paquot, N | 1 |
| Esenboga, K | 1 |
| Çiçek, ÖF | 1 |
| Oktay, AA | 1 |
| Ayral, PA | 1 |
| Gürlek, A | 1 |
| Upreti, V | 1 |
| Dhull, P | 1 |
| Patnaik, SK | 1 |
| Kumar, KV | 1 |
| Muñoz, MA | 1 |
| Liu, W | 1 |
| Delaney, JA | 1 |
| Brown, E | 1 |
| Mugavero, MJ | 1 |
| Mathews, WC | 1 |
| Napravnik, S | 1 |
| Willig, JH | 1 |
| Eron, JJ | 1 |
| Hunt, PW | 1 |
| Kahn, JO | 1 |
| Saag, MS | 1 |
| Kitahata, MM | 1 |
| Crane, HM | 1 |
| Saito, T | 2 |
| Matsunaga, A | 2 |
| Ito, K | 1 |
| Nakashima, H | 2 |
| Aslan, T | 1 |
| Erden, A | 1 |
| Karagoz, H | 1 |
| Karahan, S | 1 |
| Aykas, F | 1 |
| Uslu, E | 1 |
| Mutlu, H | 1 |
| Karaman, A | 1 |
| Raposo, HF | 1 |
| Patrício, PR | 1 |
| Simões, MC | 1 |
| Oliveira, HC | 1 |
| Salgueiro, G | 1 |
| Beltrán, LM | 1 |
| Torres, RJ | 1 |
| Puig, JG | 1 |
| Pedro-Botet, J | 1 |
| Flores-Le Roux, JA | 1 |
| Liu, X | 1 |
| Liang, S | 1 |
| Schlüter, A | 1 |
| Fourcade, S | 1 |
| Aslibekyan, S | 3 |
| Pujol, A | 1 |
| Graf, GA | 1 |
| Sun, B | 1 |
| Xie, Y | 1 |
| Jiang, J | 1 |
| Xu, X | 1 |
| Zhao, C | 1 |
| Huang, F | 1 |
| Liu, B | 1 |
| Tao, W | 1 |
| Hao, Z | 1 |
| Liu, M | 1 |
| Feng, X | 2 |
| Gao, X | 1 |
| Jia, Y | 1 |
| Zhang, H | 1 |
| Xu, Y | 1 |
| Béliard-Lasserre, S | 1 |
| Irvin, MR | 2 |
| Rotroff, DM | 1 |
| Zhi, D | 1 |
| Hidalgo, B | 1 |
| Motsinger-Reif, A | 1 |
| Marvel, S | 1 |
| Srinivasasainagendra, V | 1 |
| Claas, SA | 1 |
| Buse, JB | 1 |
| Straka, RJ | 5 |
| Ordovas, JM | 7 |
| Borecki, IB | 3 |
| Guo, X | 2 |
| Chen, IY | 1 |
| Rotter, JI | 2 |
| Wagner, MJ | 1 |
| Arnett, DK | 6 |
| Koh, KK | 5 |
| Oh, PC | 1 |
| Sakuma, I | 4 |
| Lee, Y | 4 |
| Han, SH | 5 |
| Shin, EK | 5 |
| Agarwal, M | 1 |
| Singh, VB | 1 |
| Garg, P | 1 |
| Rijhwani, P | 1 |
| Agrawal, N | 1 |
| Tak, S | 1 |
| Mittal, R | 1 |
| Daultani, P | 1 |
| Pawar, P | 1 |
| Handelsman, Y | 1 |
| Shapiro, MD | 1 |
| Cabello, I | 1 |
| Servitje, O | 1 |
| Corbella, X | 1 |
| Bardés, I | 1 |
| Pintó, X | 1 |
| Takahashi, T | 1 |
| Saegusa, Y | 1 |
| Takimoto, Y | 1 |
| Shiragami, M | 1 |
| Perez-Martinez, P | 1 |
| Corella, D | 1 |
| Shen, J | 1 |
| Yiannakouris, N | 1 |
| Tai, ES | 1 |
| Orho-Melander, M | 1 |
| Tucker, KL | 1 |
| Tsai, M | 1 |
| Province, M | 2 |
| Kai, CS | 1 |
| Perez-Jimenez, F | 1 |
| Lai, CQ | 3 |
| Lopez-Miranda, J | 1 |
| Guillen, M | 1 |
| Parnell, LD | 1 |
| Borecki, I | 3 |
| Kathiresan, S | 1 |
| Liu, Y | 2 |
| Gao, G | 3 |
| Tsai, MY | 3 |
| Zhang, K | 1 |
| Hixson, JE | 1 |
| Allison, DB | 1 |
| Mogoş, T | 1 |
| Dondoi, C | 1 |
| Musolino, A | 1 |
| Panebianco, M | 1 |
| Zendri, E | 1 |
| Santini, M | 1 |
| Di Nuzzo, S | 1 |
| Ardizzoni, A | 1 |
| Ford, ES | 1 |
| Zhao, G | 1 |
| Pearson, WS | 1 |
| Mokdad, AH | 1 |
| Cardona, F | 1 |
| Guardiola, M | 1 |
| Queipo-Ortuño, MI | 1 |
| Murri, M | 1 |
| Ribalta, J | 1 |
| Tinahones, FJ | 1 |
| Alagona, P | 1 |
| Sousa, AA | 1 |
| Kronit, HS | 1 |
| Neves, Fde A | 1 |
| Amato, AA | 1 |
| Roth, EM | 2 |
| Bays, HE | 3 |
| Forker, AD | 1 |
| Maki, KC | 3 |
| Carter, R | 1 |
| Doyle, RT | 2 |
| Stein, EA | 1 |
| Simó, R | 1 |
| Hernández, C | 1 |
| Grundy, SM | 2 |
| Vega, GL | 2 |
| Tomassini, JE | 2 |
| Tershakovec, AM | 2 |
| Cole, RP | 1 |
| Huang, XS | 1 |
| Zhao, SP | 1 |
| Bai, L | 1 |
| Hu, M | 1 |
| Zhao, W | 1 |
| Zhang, Q | 1 |
| Stein, E | 3 |
| Rozhkova, TA | 1 |
| Kukharchuk, VV | 1 |
| Titov, VN | 1 |
| Iarovaia, EB | 1 |
| Kotova, LA | 1 |
| Malyshev, PP | 1 |
| Ameliushkina, VA | 1 |
| Vivatrat, N | 1 |
| Barshop, BA | 1 |
| Jones, KL | 1 |
| Garg, R | 1 |
| Angus, E | 1 |
| Fincher, S | 1 |
| Whayne, TF | 1 |
| Sandoval, JC | 1 |
| Nakagawa-Toyama, Y | 1 |
| Tochino, Y | 1 |
| Nakaoka, H | 1 |
| Kawase, R | 1 |
| Yuasa-Kawase, M | 1 |
| Nakatani, K | 1 |
| Inagaki, M | 1 |
| Tsubakio-Yamamoto, K | 1 |
| Ishigami, M | 1 |
| Komuro, I | 1 |
| Kraja, AT | 1 |
| Province, MA | 1 |
| McKenney, JM | 1 |
| Kelly, MT | 2 |
| Setze, CM | 2 |
| Carlson, DM | 1 |
| Gold, A | 1 |
| Stolzenbach, JC | 2 |
| Williams, LA | 1 |
| Jones, PH | 2 |
| Laakso, M | 1 |
| Michie, CO | 1 |
| Sakala, M | 1 |
| Rivans, I | 1 |
| Strachan, MW | 1 |
| Clive, S | 1 |
| Saely, CH | 1 |
| Rein, P | 1 |
| Drexel, H | 1 |
| Wojczynski, MK | 1 |
| Hopkins, PN | 2 |
| Parnell, L | 1 |
| Chung, BH | 1 |
| Perkins, WJ | 1 |
| Wi, J | 1 |
| Kim, JY | 1 |
| Park, S | 1 |
| Kang, SM | 1 |
| Jang, Y | 1 |
| Chung, N | 1 |
| Shim, WH | 1 |
| Cho, SY | 1 |
| Lee, SH | 1 |
| Rosenson, RS | 4 |
| Helenowski, IB | 3 |
| Tangney, CC | 1 |
| Wan, Q | 1 |
| Wang, F | 2 |
| Guan, Q | 1 |
| Gao, L | 1 |
| Zhao, J | 1 |
| Quon, MJ | 4 |
| Lim, S | 2 |
| Lee, YH | 1 |
| Whitten, AE | 1 |
| Lorenz, RP | 1 |
| Smith, JM | 1 |
| Ballantyne, CM | 2 |
| Lele, A | 1 |
| Thakker, KM | 1 |
| Pan, SY | 3 |
| Dong, H | 3 |
| Guo, BF | 1 |
| Zhang, Y | 1 |
| Yu, ZL | 1 |
| Fong, WF | 1 |
| Han, YF | 3 |
| Ko, KM | 3 |
| Christou, GA | 1 |
| Tellis, CC | 1 |
| Elisaf, MS | 3 |
| Tselepis, AD | 2 |
| Kiortsis, DN | 1 |
| Filippatos, TD | 1 |
| Tsai, AK | 1 |
| Steffen, BT | 1 |
| Straka, R | 1 |
| Zhou, X | 1 |
| Hanson, NQ | 1 |
| Arnett, D | 1 |
| Sharpe, P | 1 |
| Večeřa, R | 1 |
| Zachařová, A | 1 |
| Orolin, J | 1 |
| Strojil, J | 1 |
| Skottová, N | 1 |
| Anzenbacher, P | 1 |
| Fenot, M | 1 |
| Sierra-Fortuny, S | 1 |
| Maillard, H | 1 |
| Rivet, J | 1 |
| Celerier, P | 1 |
| Shin, KC | 1 |
| Lee, K | 1 |
| Sunman, H | 1 |
| Canpolat, U | 1 |
| Sahiner, L | 1 |
| Aytemir, K | 1 |
| He, L | 1 |
| Yu, J | 1 |
| Li, F | 1 |
| Hao, Y | 1 |
| Mao, J | 1 |
| Hong, T | 1 |
| Chen, AF | 1 |
| Wang, X | 1 |
| Lutz, V | 1 |
| Lipsker, D | 1 |
| Izquierdo-Ortiz, MJ | 1 |
| Abaigar-Luquin, P | 1 |
| Scarisbrick, JJ | 1 |
| Morris, S | 1 |
| Azurdia, R | 1 |
| Illidge, T | 1 |
| Parry, E | 1 |
| Graham-Brown, R | 1 |
| Cowan, R | 1 |
| Gallop-Evans, E | 1 |
| Wachsmuth, R | 1 |
| Eagle, M | 1 |
| Wierzbicki, AS | 1 |
| Soran, H | 1 |
| Whittaker, S | 1 |
| Wain, EM | 1 |
| Chang, CN | 1 |
| How, CH | 1 |
| Tavintharan, S | 1 |
| Goodarzi, MO | 1 |
| Frazier-Wood, AC | 1 |
| Yan, X | 1 |
| Kim, E | 1 |
| Tiwari, HK | 1 |
| Taylor, KD | 1 |
| Korenman, SG | 1 |
| Chen, YD | 1 |
| Wooten, JS | 1 |
| Nambi, P | 1 |
| Gillard, BK | 1 |
| Pownall, HJ | 1 |
| Coraza, I | 1 |
| Scott, LW | 1 |
| Nambi, V | 1 |
| Balasubramanyam, A | 2 |
| Babbar, L | 1 |
| Mahadevan, N | 1 |
| Balakumar, P | 1 |
| Palacios, R | 1 |
| Santos, J | 1 |
| González, M | 1 |
| Ruiz, J | 1 |
| Valdivielso, P | 1 |
| Márquez, M | 1 |
| González-Santos, P | 1 |
| Sato, I | 1 |
| Hyakuta, M | 1 |
| Hayashi, F | 1 |
| Mukai, M | 1 |
| Kondo, S | 1 |
| Maeda, E | 1 |
| Kumagai, S | 1 |
| Capell, WH | 1 |
| DeSouza, CA | 1 |
| Poirier, P | 1 |
| Bell, ML | 1 |
| Stauffer, BL | 1 |
| Weil, KM | 1 |
| Hernandez, TL | 1 |
| Eckel, RH | 1 |
| Nagra, PK | 1 |
| Ho, AC | 1 |
| Dugan, JD | 1 |
| Takahashi, S | 1 |
| Moriwaki, Y | 1 |
| Yamamoto, T | 1 |
| Tsutsumi, Z | 1 |
| Ka, T | 1 |
| Fukuchi, M | 1 |
| Cottrell, DA | 1 |
| Marshall, BJ | 1 |
| Falko, JM | 1 |
| Marchesi, S | 1 |
| Lupattelli, G | 1 |
| Lombardini, R | 1 |
| Roscini, AR | 1 |
| Siepi, D | 1 |
| Vaudo, G | 1 |
| Sinzinger, H | 1 |
| Schillaci, G | 1 |
| Mannarino, E | 1 |
| Huang, Y | 1 |
| Dai, G | 2 |
| Feng, Z | 2 |
| Lu, C | 1 |
| Cheng, B | 1 |
| Nie, F | 1 |
| Li, J | 2 |
| Sedova, L | 1 |
| Seda, O | 1 |
| Krenova, D | 1 |
| Kren, V | 1 |
| Kazdova, L | 1 |
| Badiou, S | 1 |
| Merle De Boever, C | 1 |
| Dupuy, AM | 1 |
| Baillat, V | 1 |
| Cristol, JP | 1 |
| Reynes, J | 1 |
| Tsimihodimos, V | 1 |
| Kostoula, A | 1 |
| Kakafika, A | 1 |
| Bairaktari, E | 1 |
| Mikhailidis, DP | 2 |
| Elisaf, M | 1 |
| Jeong, S | 1 |
| Kim, M | 2 |
| Han, M | 1 |
| Lee, H | 1 |
| Ahn, J | 1 |
| Song, YH | 1 |
| Shin, C | 1 |
| Nam, KH | 1 |
| Kim, TW | 1 |
| Oh, GT | 1 |
| Yoon, M | 1 |
| Kon Koh, K | 1 |
| Yeal Ahn, J | 2 |
| Hwan Han, S | 1 |
| Kyu Jin, D | 1 |
| Sik Kim, H | 1 |
| Cheon Lee, K | 1 |
| Kyun Shin, E | 1 |
| Rao, A | 1 |
| D'Amico, S | 1 |
| Maldonado, M | 1 |
| Ikewaki, K | 1 |
| Tohyama, J | 1 |
| Nakata, Y | 1 |
| Wakikawa, T | 1 |
| Kido, T | 1 |
| Mochizuki, S | 1 |
| Cicero, AF | 2 |
| Derosa, G | 2 |
| Miconi, A | 2 |
| Laghi, L | 2 |
| Nascetti, S | 2 |
| Gaddi, A | 2 |
| Ye, P | 1 |
| Li, JJ | 1 |
| Su, G | 1 |
| Davidson, MH | 2 |
| Bays, H | 1 |
| Rhyne, J | 1 |
| Rotenberg, K | 1 |
| Doyle, R | 2 |
| Ko, HS | 1 |
| Kim, CJ | 2 |
| Ryu, WS | 1 |
| Ruel, IL | 1 |
| Lamarche, B | 3 |
| Mauger, JF | 1 |
| Badellino, KO | 1 |
| Cohn, JS | 3 |
| Marcil, M | 1 |
| Couture, P | 3 |
| Chung, WJ | 1 |
| Ahn, JY | 1 |
| Kim, JA | 1 |
| Yang, TL | 1 |
| Chen, MF | 1 |
| Xia, X | 1 |
| Luo, BL | 1 |
| Li, YJ | 1 |
| Srivastava, RA | 1 |
| Jahagirdar, R | 1 |
| Azhar, S | 1 |
| Sharma, S | 1 |
| Bisgaier, CL | 1 |
| Fruchart, JC | 2 |
| Duriez, P | 1 |
| Li, WY | 1 |
| Zhao, XY | 1 |
| Yang, R | 1 |
| Feng, XD | 1 |
| Li, N | 1 |
| Geng, W | 1 |
| Shalwitz, RA | 1 |
| Paul, S | 1 |
| Mohan, V | 1 |
| Usman, M | 1 |
| Peter, R | 1 |
| Christidis, DS | 1 |
| Liberopoulos, EN | 1 |
| Kakafika, AI | 1 |
| Miltiadous, GA | 1 |
| Cariolou, M | 1 |
| Ganotakis, ES | 1 |
| Oki, K | 1 |
| Koide, J | 1 |
| Nakanishi, S | 1 |
| Nakashima, R | 1 |
| Yamane, K | 1 |
| Wolff, DA | 2 |
| Huskin, AL | 2 |
| Rademaker, AW | 2 |
| Gerber, JG | 1 |
| Kitch, DW | 1 |
| Fichtenbaum, CJ | 1 |
| Zackin, RA | 1 |
| Charles, S | 1 |
| Hogg, E | 1 |
| Acosta, EP | 1 |
| Connick, E | 1 |
| Wohl, D | 1 |
| Kojic, EM | 1 |
| Benson, CA | 1 |
| Aberg, JA | 1 |
| Vilà, L | 1 |
| Roglans, N | 1 |
| Alegret, M | 1 |
| Camins, A | 1 |
| Pallàs, M | 1 |
| Sánchez, RM | 1 |
| Vázquez-Carrera, M | 1 |
| Laguna, JC | 1 |
| Hogue, JC | 2 |
| Deshaies, Y | 1 |
| Tremblay, AJ | 2 |
| Bergeron, J | 2 |
| Gagné, C | 2 |
| McQuade, CR | 1 |
| Griego, J | 1 |
| Anderson, J | 1 |
| Pai, AB | 1 |
| Mombelli, G | 1 |
| Banfi, F | 1 |
| Falcioni, S | 1 |
| Sirtori, CR | 1 |
| Skrha, J | 1 |
| Sindelka, G | 1 |
| Haas, T | 1 |
| Hilgertová, J | 1 |
| Justová, V | 1 |
| Farnier, M | 1 |
| Bonnefous, F | 1 |
| Debbas, N | 1 |
| Irvine, A | 1 |
| Shepherd, J | 1 |
| Otto, C | 1 |
| Ritter, MM | 1 |
| Soennichsen, AC | 1 |
| Schwandt, P | 1 |
| Richter, WO | 1 |
| Dierkes, J | 2 |
| Westphal, S | 2 |
| Luley, C | 2 |
| Genest, J | 2 |
| Nguyen, NH | 1 |
| Theroux, P | 1 |
| Davignon, J | 1 |
| Yang, Y | 1 |
| Wei, W | 1 |
| Zhou, B | 1 |
| Thomas, JC | 1 |
| Lopes-Virella, MF | 1 |
| Del Bene, VE | 1 |
| Cerveny, JD | 1 |
| Taylor, KB | 1 |
| McWhorter, LS | 1 |
| Bultemeier, NC | 1 |
| Idzior-Walus, B | 1 |
| Sieradzki, J | 1 |
| Rostworowski, W | 1 |
| Zdzienicka, A | 1 |
| Kawalec, E | 1 |
| Wójcik, J | 1 |
| Zarnecki, A | 1 |
| Blane, G | 1 |
| Fornengo, P | 1 |
| Bruno, A | 1 |
| Gambino, R | 1 |
| Cassader, M | 1 |
| Pagano, G | 1 |
| Bissonnette, R | 1 |
| Treacy, E | 1 |
| Rozen, R | 1 |
| Boucher, B | 1 |
| Bae, JH | 1 |
| Bassenge, E | 1 |
| Lee, HJ | 1 |
| Park, KR | 1 |
| Park, CG | 1 |
| Park, KY | 1 |
| Lee, MS | 1 |
| Schwemmer, M | 1 |
| Fartoux-Heymann, L | 1 |
| Narcy-Lambare, B | 1 |
| Labayle, D | 1 |
| Fischer, D | 1 |
| Chan, NN | 1 |
| Chow, FC | 1 |
| Yamada, N | 1 |
| Brisson, D | 1 |
| Ledoux, K | 1 |
| Bossé, Y | 1 |
| St-Pierre, J | 1 |
| Julien, P | 1 |
| Perron, P | 1 |
| Hudson, TJ | 1 |
| Vohl, MC | 1 |
| Gaudet, D | 1 |
| Zeman, M | 2 |
| Zák, A | 2 |
| Tvrzická, E | 2 |
| Konárková, M | 2 |
| Stípek, S | 1 |
| Vecka, M | 1 |
| Romaniv, S | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Malmendier, CL | 1 |
| Lontie, JF | 1 |
| Delcroix, C | 1 |
| Dubois, DY | 1 |
| Magot, T | 1 |
| De Roy, L | 1 |
| Olivier, P | 1 |
| Plancke, MO | 1 |
| Theret, N | 1 |
| Marzin, D | 1 |
| Clavey, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)[NCT02781584] | Phase 2 | 220 participants (Actual) | Interventional | 2016-06-13 | Completed | ||
| A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy[NCT02314533] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| The Boston Puerto Rican Health Study: Center for Population Health and Health Disparities[NCT01231958] | 1,650 participants (Actual) | Observational | 2004-06-30 | Completed | |||
| Time to Complications Occurs in Diabetes. Risk Factors Determine When Diabetes Complications Occur[NCT00969956] | 17 participants (Actual) | Observational | 2012-04-30 | Terminated (stopped due to Local regulations) | |||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Omacor Therapy in Hypertriglyceridemic Subjects Treated With Antara, Followed by an 8-week Extension[NCT00246636] | Phase 4 | 167 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™[NCT00891293] | Phase 4 | 93 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Tolerability and Efficacy of the Co-Administration of Simvastatin 20 mg/Day and Fenofibrate 160 mg/Day Compared to Simvastatin 20 mg/Day Alone for 12 Weeks of Treatment in Patie[NCT00092157] | Phase 3 | 571 participants (Actual) | Interventional | 2002-05-01 | Completed | ||
| An 8-Week, Multicenter, Randomized, Double-blind, Four-arm, Parallel-group Study Comparing the Safety and Efficacy of ABT-143 to Simvastatin in Subjects With Hypercholesterolemia[NCT00812955] | Phase 3 | 474 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376] | 221 participants (Actual) | Interventional | 2004-01-31 | Completed | |||
| A Phase II Trial of the Effect of Combination Therapy With Fish Oil Supplement and Fenofibrate on Triglyceride (TG) Levels in Subjects on Highly Active Antiretroviral Therapy (HAART) Who Are Not Responding to Either Fish Oil or Fenofibrate Alone[NCT00076518] | Phase 2 | 100 participants | Interventional | Completed | |||
| Role of Omega-3 Fish Oil Fatty Acids on Depression Among HIV-seropositive Pregnant Pregnant Women in Nairobi: A Randomized Double-blind Controlled Trial[NCT01614249] | 216 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00884819] | 4 participants (Actual) | Interventional | 2008-12-31 | Terminated (stopped due to Poor recruitment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days for subjects who permanently discontinued study drug. If baseline laboratory data were missing, then any abnormality of at least Grade 1 was considered treatment emergent. Graded laboratory abnormalities were defined using the grading scheme in the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 for Cohorts 1-9 and CTCAE Version 5.0 for Cohorts 10-13. (NCT02781584)
Timeframe: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: SEL 18 mg (Non-cirrhotic) | 20 |
| Cohort 2: FIR 20 mg (Non-cirrhotic) | 20 |
| Cohort 3: CILO 30 mg (Non-cirrhotic) | 40 |
| Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | 10 |
| Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | 20 |
| Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | 10 |
| Cohort 7: CILO 20 mg (Cirrhotic) | 40 |
| Cohort 8: CILO 30 mg (Cirrhotic) | 30 |
| Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | 15.4 |
| Cohort 10: FIR 20 mg + FENO 48 mg | 6.7 |
| Cohort 11: FIR 20 mg + FENO 145 mg | 12.5 |
| Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | 6.7 |
| Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg | 6.3 |
"A treatment emergent serious adverse event (SAE) was defined as an event that, at any dose, results in the following:~Death~Life-threatening~In-patient hospitalization or prolongation of existing hospitalization~Persistent or significant disability/incapacity~A congenital anomaly/birth defect~A medically important event or reaction" (NCT02781584)
Timeframe: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: SEL 18 mg (Non-cirrhotic) | 0 |
| Cohort 2: FIR 20 mg (Non-cirrhotic) | 0 |
| Cohort 3: CILO 30 mg (Non-cirrhotic) | 0 |
| Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | 5 |
| Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | 5 |
| Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | 5 |
| Cohort 7: CILO 20 mg (Cirrhotic) | 10 |
| Cohort 8: CILO 30 mg (Cirrhotic) | 0 |
| Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | 7.69 |
| Cohort 10: FIR 20 mg + FENO 48 mg | 0 |
| Cohort 11: FIR 20 mg + FENO 145 mg | 0 |
| Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | 3.33 |
| Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg | 3.12 |
"Treatment-emergent AEs were defined as events that met 1 or both of the following criteria:~Any AEs with onset dates on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug~Any AEs leading to premature discontinuation of study drug" (NCT02781584)
Timeframe: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1: SEL 18 mg (Non-cirrhotic) | 50 |
| Cohort 2: FIR 20 mg (Non-cirrhotic) | 60 |
| Cohort 3: CILO 30 mg (Non-cirrhotic) | 50 |
| Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | 25 |
| Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | 40 |
| Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | 50 |
| Cohort 7: CILO 20 mg (Cirrhotic) | 80 |
| Cohort 8: CILO 30 mg (Cirrhotic) | 70 |
| Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | 76.92 |
| Cohort 10: FIR 20 mg + FENO 48 mg | 86.67 |
| Cohort 11: FIR 20 mg + FENO 145 mg | 87.5 |
| Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | 40 |
| Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg | 37.5 |
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
Median Percent Change in apolipoprotein (apo) A-1 from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of apo A-1 from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24
| Intervention | Percentage change (Median) | |
|---|---|---|
| LOV111859/OM5 Baseline to LOV111860/OM5X EOT | LOV111859/OM5 Baseline to LOV111821/OM5XX EOT | |
| Lovaza (Formerly Known as Omacor) and Fenofibrate | 1.7 | 2.9 |
Median Percent Change in apolipoprotein (apo) B from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of apo B from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24
| Intervention | Percentage change (Median) | |
|---|---|---|
| LOV111859/OM5 Baseline to LOV111860/OM5X EOT | LOV111859/OM5 Baseline to LOV111821/OM5XX EOT | |
| Lovaza (Formerly Known as Omacor) and Fenofibrate | 0.0 | -7.3 |
Median Percent Change in high density lipoprotein-cholesterol (HDL-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of HDL-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24
| Intervention | Percentage change (Median) | |
|---|---|---|
| LOV111859/OM5 Baseline to LOV111860/OM5X EOT | LOV111859/OM5 Baseline to LOV111821/OM5XX EOT | |
| Lovaza (Formerly Known as Omacor) and Fenofibrate | -3.0 | -11.1 |
Median Percent Change in low density lipoprotein-cholesterol (LDL-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of LDL-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24
| Intervention | Percentage change (Median) | |
|---|---|---|
| LOV111859/OM5 Baseline to LOV111860/OM5X EOT | LOV111859/OM5 Baseline to LOV111821/OM5XX EOT | |
| Lovaza (Formerly Known as Omacor) and Fenofibrate | 52.8 | 37.5 |
Median Percent Change of non- high density lipoprotein-cholesterol (non-HDL-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of non-HDL-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24
| Intervention | Percentage change (Median) | |
|---|---|---|
| LOV111859/OM5 Baseline to LOV111860/OM5X EOT | LOV111859/OM5 Baseline to LOV111821/OM5XX EOT | |
| Lovaza (Formerly Known as Omacor) and Fenofibrate | -7.2 | -13.3 |
Median Percent Change in the ratio of total cholesterol (Total-C) to high density lipoprotein-cholesterol (HDL-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change for the ratio of Total-C to HDL-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24
| Intervention | Percentage change (Median) | |
|---|---|---|
| LOV111859/OM5 Baseline to LOV111860/OM5X EOT | LOV111859/OM5 Baseline to LOV111821/OM5XX EOT | |
| Lovaza (Formerly Known as Omacor) and Fenofibrate | -4.8 | 0 |
Median Percent Change in Serum Triglycerides from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of Serum Triglycerides from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24
| Intervention | Percentage change (Median) | |
|---|---|---|
| LOV111859/OM5 Baseline to LOV111860/OM5X EOT | LOV111859/OM5 Baseline to LOV111821/OM5XX EOT | |
| Lovaza (Formerly Known as Omacor) and Fenofibrate | -60.6 | -62.0 |
Median Percent Change in Total Cholesterol (Total-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of Total-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24
| Intervention | Percentage change (Median) | |
|---|---|---|
| LOV111859/OM5 Baseline to LOV111860/OM5X EOT | LOV111859/OM5 Baseline to LOV111821/OM5XX EOT | |
| Lovaza (Formerly Known as Omacor) and Fenofibrate | -6.7 | -13.2 |
Median Percent Change in very low density lipoprotein-cholesterol (VLDL-C) from the baseline of LOV111859/OM5 to the End-of-Treatment (EOT) (Week 8) of LOV111860/OM5X and Median Percent Change of VLDL-C from the baseline of LOV111859/OM5 to the EOT (Month 24) of LOV111821/OM5XX. (NCT00891293)
Timeframe: LOV111859/OM5 Baseline to LOV111860/OM5X Week 8 and LOV111859/OM5 Baseline to LOV111821/OM5XX Month 24
| Intervention | Percentage change (Median) | |
|---|---|---|
| LOV111859/OM5 Baseline to LOV111860/OM5X EOT | LOV111859/OM5 Baseline to LOV111821/OM5XX EOT | |
| Lovaza (Formerly Known as Omacor) and Fenofibrate | -58.3 | -54.6 |
"The mean percent change from Baseline to the Final Visit in low-density lipoprotein cholesterol, comparing the following two treatment groups:~ABT-143 capsules 20/135 milligrams versus simvastatin capsules 40 milligrams for the full analysis set." (NCT00812955)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Mean) |
|---|---|
| Simvastatin Capsules 40 mg | -32.8 |
| ABT-143 Capsules 20/135 mg | -47.2 |
The mean percent change from Baseline to the Final Visit in low-density lipoprotein cholesterol, comparing the following treatment groups, ABT-143 capsules 10/135 milligrams versus simvastatin capsules 40 milligrams for the full analysis set. (NCT00812955)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Mean) |
|---|---|
| Simvastatin Capsules 40 mg | -32.8 |
| ABT-143 Capsules 10/135 mg | -46.0 |
The mean percent change from Baseline to the Final Visit in low-density lipoprotein cholesterol, comparing the following treatment groups, ABT-143 capsules 5/135 milligrams versus simvastatin capsules 40 milligrams for the full analysis set. (NCT00812955)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Mean) |
|---|---|
| Simvastatin Capsules 40 mg | -32.8 |
| ABT-143 Capsules 5/135 mg | -38.9 |
The ABT-143 capsules 20/135 milligram, ABT-143 capsules 10/135 milligram, and ABT-143 capsules 5/135 milligram groups were compared to the simvastatin capsules 40 milligram group for mean percent change in high-density lipoprotein cholesterol from Baseline to the Final Visit for the full analysis set. (NCT00812955)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Mean) |
|---|---|
| Simvastatin Capsules 40 mg | 9.6 |
| ABT-143 Capsules 5/135 mg | 16.2 |
| ABT-143 Capsules 10/135 mg | 14.0 |
| ABT-143 Capsules 20/135 mg | 15.7 |
The ABT-143 capsules 20/135 milligram, ABT-143 capsules 10/135 milligram, and ABT-143 capsules 5/135 milligram groups were compared to the simvastatin capsules 40 milligram group for median percent change in triglycerides from Baseline to the Final Visit for the full analysis set. (NCT00812955)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Median) |
|---|---|
| Simvastatin Capsules 40 mg | -20.8 |
| ABT-143 Capsules 5/135 mg | -42.7 |
| ABT-143 Capsules 10/135 mg | -44.6 |
| ABT-143 Capsules 20/135 mg | -50.0 |
HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Group 1 - Usual Care | 37.1 |
| Group 2 - Diet/Exercise Only | 38.7 |
| Group 3 - Diet/Exercise + Fenofibrate | 40.7 |
| Group 4 - Diet/Exercise + Niacin | 41.8 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 44.8 |
non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Group 1 - Usual Care | 162.2 |
| Group 2 - Diet/Exercise Only | 165.4 |
| Group 3 - Diet/Exercise + Fenofibrate | 145.8 |
| Group 4 - Diet/Exercise + Niacin | 154 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 137.1 |
Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Group 1 - Usual Care | 195.6 |
| Group 2 - Diet/Exercise Only | 200.1 |
| Group 3 - Diet/Exercise + Fenofibrate | 184 |
| Group 4 - Diet/Exercise + Niacin | 190.8 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 178.4 |
Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | ratio (Mean) |
|---|---|
| Group 1 - Usual Care | 5.2 |
| Group 2 - Diet/Exercise Only | 5.1 |
| Group 3 - Diet/Exercise + Fenofibrate | 4.5 |
| Group 4 - Diet/Exercise + Niacin | 4.6 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 4 |
Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Group 1 - Usual Care | 199 |
| Group 2 - Diet/Exercise Only | 216.9 |
| Group 3 - Diet/Exercise + Fenofibrate | 155.1 |
| Group 4 - Diet/Exercise + Niacin | 177.6 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 135.6 |
"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Body cell mass | Fat mass | |
| Group 1 - Usual Care | 59.6 | 36.8 |
| Group 2 - Diet/Exercise | 67.3 | 37.5 |
| Group 3 - Diet/Exercise + Fenofibrate | 66.6 | 35.8 |
| Group 4 - Diet/Exercise + Niacin | 67.1 | 37.7 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 68.2 | 36.2 |
Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks
| Intervention | micrograms/ml (Mean) | |||
|---|---|---|---|---|
| Fasting insulin | HOMA-IR | Insulin sensitvity index | Adiponectin | |
| Group 1 - Usual Care | 8.7 | 1.92 | 3.54 | 7.12 |
| Group 2 - Diet/Exercise Only | 6.7 | 1.38 | 4.95 | 6.04 |
| Group 3 - Diet/Exercise + Fenofibrate | 9.5 | 2.02 | 3.81 | 5.24 |
| Group 4 - Diet/Exercise + Niacin | 11.9 | 2.76 | 2.88 | 11.01 |
| Group 5 - Diet/Exercise + Fenofibrate + Niacin | 10.3 | 2.38 | 2.38 | 10.34 |
Depressive symptoms were assessed by Beck Depression Inventory Second Edition (BDI-II) Scoring scale at Baseline and end of study during the 8- week study period. The BDI-II Scale is a 21-item scoring tool which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represent a depressive symptom. The symptoms are each scored on a 4-point Likert scale of 0 to 3 (0=symptom is absent; 3=symptom is severe).Scores for each symptom are added up to obtain the total scores for all 21 items, which are interpreted as follows: Scores of 0-13: minimal depression; 14-19: mild depression; 20-28: moderate depression and 29-63: severe depression. The change in BDI-II scores were computed from post-intervention scores at week 8 and baseline BDI-II scores at week 0. (NCT01614249)
Timeframe: 8 weeks
| Intervention | scores on BDI-II scale (Mean) |
|---|---|
| Soybean Oil Soft Gels Control Group | -13.9 |
| Fish Oil Omega-3 EPA-rich Soft Gels Experimental Group | -13.3 |
20 reviews available for fenofibrate and Hypertriglyceridemia
| Article | Year |
|---|---|
Control of the overall lipid profile.
Topics: Apolipoproteins B; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemi | 2019 |
Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis.
Topics: Fenofibrate; Humans; Hypertriglyceridemia; Treatment Outcome; Uric Acid | 2021 |
Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: A rare case report and literature review.
Topics: Adult; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Hypothyroidism; Rhab | 2018 |
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Topics: Atherosclerosis; Cell Membrane; Cholesterol, LDL; Coronary Thrombosis; Docosahexaenoic Acids; Eicosa | 2019 |
Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials.
Topics: Apolipoprotein C-III; Cardiovascular Diseases; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipide | 2019 |
Topics in lipoprotein glomerulopathy: an overview.
Topics: Apolipoprotein E2; Apolipoproteins E; Fenofibrate; Founder Effect; Humans; Hypertriglyceridemia; Kid | 2014 |
[New evolution in lipoprotein glomerulopathy].
Topics: Animals; Apolipoproteins E; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Kidney | 2013 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Caus | 2015 |
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Topics: Atherosclerosis; Cardiovascular Diseases; Fatty Acids, Omega-3; Fenofibrate; Fibric Acids; Humans; H | 2017 |
Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Humans; Hydroxymethylgluta | 2009 |
Advances in the medical treatment of diabetic retinopathy.
Topics: Blindness; Blood-Retinal Barrier; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Dia | 2009 |
Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Blood Glucose; Capecitabine; Colonic Neoplasms; Deoxycytidine; Feno | 2009 |
Fenofibrate and metabolic syndrome.
Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hydroxymethylglu | 2010 |
Lipid disorders in type 2 diabetes.
Topics: Atherosclerosis; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Hu | 2009 |
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.
Topics: Adult; Cardiovascular Diseases; Diabetes Complications; Drug Combinations; Drug Monitoring; Dyslipid | 2011 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2003 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, | 2006 |
Mechanism of action of fibrates.
Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Huma | 1993 |
[Fibrates].
Topics: Bezafibrate; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents | 2002 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
57 trials available for fenofibrate and Hypertriglyceridemia
| Article | Year |
|---|---|
Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease.
Topics: Adult; Aged; Carboxylic Acids; Fatty Acids, Omega-3; Female; Fenofibrate; Humans; Hypertriglyceridem | 2021 |
Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
Topics: Acetyl-CoA Carboxylase; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Liver Cirrh | 2023 |
Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
Topics: Adult; Double-Blind Method; Fenofibrate; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemi | 2022 |
Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia.
Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fenofibrate; Gl | 2020 |
Fenofibrate treatment for severe hypertriglyceridemia in dogs.
Topics: Animals; Diet, Fat-Restricted; Dog Diseases; Dogs; Fenofibrate; Gene Expression Regulation; Glucose | 2021 |
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Topics: Benzoxazoles; Biomarkers; Butyrates; Cholesterol, HDL; Double-Blind Method; Female; Fenofibrate; Fol | 2018 |
Effect of fenofibrate on serum nitric oxide levels in patients with hypertriglyceridemia.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Fenofibrate; Humans; Hypertriglyceridemia; Hypo | 2019 |
Vascular and metabolic effects of omega-3 fatty acids combined with fenofibrate in patients with hypertriglyceridemia.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Monitoring; Drug Therapy, | 2016 |
Choline Fenofibrate Delayed Release Capsules Versus Conventional Fenofibrate Tablets for Dyslipidemia: A Randomized, Non-Inferiority Trial.
Topics: Adult; Biological Availability; Capsules; Choline; Delayed-Action Preparations; Drug Monitoring; Fem | 2015 |
Which dose of omega-3 fatty acids must be taken in different cases of hypertriglyceridemia?
Topics: Dose-Response Relationship, Drug; Fatty Acids, Omega-3; Female; Fenofibrate; Heart Diseases; Humans; | 2008 |
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
Topics: Adolescent; Adult; Aged; Body Mass Index; Combined Modality Therapy; Diet Records; Diet, Fat-Restric | 2009 |
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
Topics: Adolescent; Adult; Aged; Body Mass Index; Combined Modality Therapy; Diet Records; Diet, Fat-Restric | 2009 |
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
Topics: Adolescent; Adult; Aged; Body Mass Index; Combined Modality Therapy; Diet Records; Diet, Fat-Restric | 2009 |
Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
Topics: Adolescent; Adult; Aged; Body Mass Index; Combined Modality Therapy; Diet Records; Diet, Fat-Restric | 2009 |
Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
Topics: Adult; Aged; Apolipoproteins B; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Hu | 2009 |
The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
Topics: Adult; Aged; Body Weight; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combinati | 2009 |
[Treatment of patients with hypertriglyceridemia].
Topics: Adult; Aged; Cholesterol; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; M | 2009 |
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug | 2010 |
Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.
Topics: Apolipoproteins B; Female; Fenofibrate; Genotype; Humans; Hypertriglyceridemia; Male; Middle Aged; P | 2010 |
Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Female; Fenofibrate; Fibric Ac | 2010 |
Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Female; Fenofibrate; Hum | 2010 |
Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial.
Topics: Adolescent; Adult; Aged; Blood Glucose; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypoglyce | 2010 |
Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia.
Topics: Adipokines; Biomarkers; Cross-Over Studies; Female; Fenofibrate; Hemoglobins; Humans; Hypertriglycer | 2011 |
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Dr | 2011 |
Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).
Topics: Apolipoproteins B; Cholesterol, LDL; Drug Therapy, Combination; Fenofibrate; Humans; Hydroxymethylgl | 2011 |
The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment.
Topics: Adult; Apolipoproteins B; Caloric Restriction; Diet, Fat-Restricted; Female; Fenofibrate; Humans; Hy | 2012 |
Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.
Topics: Adiponectin; Analysis of Variance; Apolipoprotein A-I; Biomarkers; Blood Glucose; C-Reactive Protein | 2012 |
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Antiretroviral Therapy, Highly Active; | 2013 |
Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Fenofibrate; HIV Infect | 2002 |
Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Fenofib | 2003 |
Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
Topics: Adult; Angiotensin Receptor Antagonists; Drug Therapy, Combination; Fenofibrate; Gout Suppressants; | 2003 |
Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia.
Topics: Adult; Cell Adhesion Molecules; Dietary Fats; Endothelium, Vascular; Fasting; Female; Fenofibrate; H | 2003 |
Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
Topics: Adult; Anti-Retroviral Agents; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins B; Apolipop | 2004 |
Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Arteriosclerosis; Biomarkers; C-Reactive Prot | 2004 |
Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis.
Topics: Adult; Biomarkers; C-Reactive Protein; Cardiovascular Physiological Phenomena; Cross-Over Studies; D | 2004 |
Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study.
Topics: Adult; Aged; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Humans; Hypertriglyceridem | 2004 |
Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.
Topics: Adiponectin; Blood Flow Velocity; Body Mass Index; Brachial Artery; Cross-Over Studies; Double-Blind | 2005 |
Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates.
Topics: Adult; Blood Pressure; Cholesterol; Coenzymes; Creatinine; Drug Resistance; Drug Therapy, Combinatio | 2005 |
Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia.
Topics: Blood Pressure; C-Reactive Protein; Cytokines; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hy | 2005 |
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Topics: Capsules; Cholesterol, HDL; Cholesterol, VLDL; Diarrhea; Double-Blind Method; Drug Administration Sc | 2005 |
Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Case-Control Studies; Cholesterol, HDL; Fem | 2005 |
Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2006 |
Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia.
Topics: Adult; Anticholesteremic Agents; Arginine; Blood Flow Velocity; Brachial Artery; Cholesterol; Choles | 2006 |
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.
Topics: Adult; Aged; Atherosclerosis; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fenofibr | 2006 |
Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients.
Topics: C-Reactive Protein; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyp | 2006 |
Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia.
Topics: Adiponectin; Administration, Oral; Adult; Blood Glucose; Cytokines; Fenofibrate; Humans; Hypertrigly | 2007 |
Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
Topics: Adult; Apolipoproteins B; Blood Glucose; Blood Pressure; Double-Blind Method; Fatty Acids, Nonesteri | 2007 |
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Fish Oils | 2008 |
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Fish Oils | 2008 |
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Fish Oils | 2008 |
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Fish Oils | 2008 |
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Atorvastatin; Cholesterol; Diab | 2008 |
Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.
Topics: Aged; Cytokines; Double-Blind Method; Fasting; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hy | 2008 |
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Female; Fenofibrate; H | 2008 |
Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Dose-Response Relationship, Drug; Double-Blin | 2008 |
Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Female; Fe | 1994 |
Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia.
Topics: Adult; Blood Physiological Phenomena; Blood Viscosity; Fatty Acids, Omega-3; Female; Fenofibrate; Hu | 1996 |
Serum homocysteine increases after therapy with fenofibrate or bezafibrate.
Topics: Adult; Bezafibrate; Chromatography, High Pressure Liquid; Fenofibrate; Folic Acid; Hematinics; Homoc | 1999 |
Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.
Topics: Adult; Area Under Curve; Cholesterol, HDL; Double-Blind Method; Fasting; Fenofibrate; Hemostasis; Hu | 2000 |
Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Glucose; Blood | 2000 |
Fenofibrate raises plasma homocysteine levels in the fasted and fed states.
Topics: Adult; Coronary Artery Disease; Dairy Products; Dietary Fats; Double-Blind Method; Eating; Fasting; | 2001 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Adult; Aged; Creatinine; Cross-Over Studies; Cystatin C; Cystatins; Fenofibrate; Gemfibrozil; Homocy | 2001 |
Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Coronary Artery Disease; Dietary Fats | 2001 |
90 other studies available for fenofibrate and Hypertriglyceridemia
| Article | Year |
|---|---|
Synthetic studies of cis-4-Amino-L-proline derivatives as novel lipid lowering agents.
Topics: Animals; Hypertriglyceridemia; Hypolipidemic Agents; Mice; Proline; Pyrimidinones; Quinazolines; Str | 2002 |
Clinical features and functions of a novel Lpl mutation C.986A>C (p.Y329S) in patient with hypertriglyceridemia.
Topics: Cholesterol; DNA; Fenofibrate; Humans; Hypertriglyceridemia; Lipoprotein Lipase; Mutation; Triglycer | 2022 |
Topics: Adolescent; Adult; Animals; Biomarkers; Cat Diseases; Catalysis; Cats; Child; Emotions; Fenofibrate; | 2022 |
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
Topics: Acetates; Acetyl-CoA Carboxylase; Animals; Fenofibrate; Humans; Hypertriglyceridemia; Liver Cirrhosi | 2022 |
Hypertriglyceridaemia in pregnancy: an unexpected diagnosis and its management.
Topics: Diet, Fat-Restricted; Female; Fenofibrate; Humans; Hyperlipidemias; Hypertriglyceridemia; Pregnancy | 2022 |
Successful multimodal treatment of extreme hypertriglyceridemia in a juvenile diabetic dog.
Topics: Animals; Combined Modality Therapy; Diabetes Mellitus; Diabetic Ketoacidosis; Dog Diseases; Dogs; Fe | 2023 |
Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
Topics: Bezafibrate; Drug Substitution; Fenofibrate; Humans; Hypertriglyceridemia; Renal Insufficiency; Rena | 2023 |
Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database.
Topics: Aged; Chemical and Drug Induced Liver Injury; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidem | 2020 |
Acquired marked hypertriglyceridemia with anti-GPIHBP1 antibodies.
Topics: Adolescent; Anti-Inflammatory Agents; Autoantibodies; Diet, Fat-Restricted; Female; Fenofibrate; Hum | 2020 |
Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature.
Topics: Aged; Diabetes Mellitus; Female; Fenofibrate; Humans; Hypertriglyceridemia; Pancreatitis; Rhabdomyol | 2020 |
Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cost of Illness; Di | 2020 |
A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice.
Topics: Animals; Chylomicrons; Diet, High-Fat; Fenofibrate; Hypertriglyceridemia; Hypolipidemic Agents; Male | 2018 |
The Effect of Hypolipidemic Agents on Thyroid Autoimmunity in Women with Hashimoto's Thyroiditis Treated with Levothyroxine and Selenomethionine.
Topics: Adult; Autoantibodies; Autoimmunity; Female; Fenofibrate; Hashimoto Disease; Humans; Hydroxymethylgl | 2018 |
Capecitabine-induced pancreatitits.
Topics: Abdomen, Acute; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modali | 2018 |
Investigation of parent-of-origin effects induced by fenofibrate treatment on triglycerides levels.
Topics: CpG Islands; DNA Methylation; Epigenomics; Fenofibrate; Genome-Wide Association Study; Humans; Hyper | 2018 |
Comparison of novel and existing methods for detecting differentially methylated regions.
Topics: Carnitine O-Palmitoyltransferase; CpG Islands; DNA Methylation; Epigenomics; ETS Translocation Varia | 2018 |
Modification effect of fenofibrate therapy, a longitudinal epigenomic-wide methylation study of triglycerides levels in the GOLDN study.
Topics: Carnitine O-Palmitoyltransferase; CpG Islands; DNA Methylation; Epigenesis, Genetic; Fenofibrate; Ge | 2018 |
Causal modeling in a multi-omic setting: insights from GAW20.
Topics: Bayes Theorem; Carnitine O-Palmitoyltransferase; Cholesterol, HDL; DNA Methylation; Fenofibrate; Gen | 2018 |
Detecting responses to treatment with fenofibrate in pedigrees.
Topics: CpG Islands; DNA Methylation; Drug Administration Schedule; Epigenomics; Fenofibrate; Genome-Wide As | 2018 |
[Management of hypertriglyceridaemia].
Topics: Diabetes Mellitus, Type 2; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents | 2019 |
An unusual cause of delayed puberty: Berardinelli- Seip syndrome.
Topics: Administration, Cutaneous; Adolescent; Atorvastatin; Combined Modality Therapy; Diet, Fat-Restricted | 2012 |
Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.
Topics: Adult; Alabama; Atorvastatin; California; CD4-Positive T-Lymphocytes; Cohort Studies; Comparative Ef | 2013 |
An acute edematous pancreatitis case developed on the basis of hypertriglyceridemia.
Topics: Adult; Anticoagulants; Diabetes Mellitus, Type 2; Enzyme Activation; Female; Fenofibrate; Heparin; H | 2013 |
Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.
Topics: Animals; Bezafibrate; Cholesterol Ester Transfer Proteins; Combined Modality Therapy; Corn Oil; Cros | 2014 |
Fenofibrate increases serum creatinine in a patient with familial nephropathy associated to hyperuricemia.
Topics: Adult; Creatinine; Female; Fenofibrate; Gout; Humans; Hypertriglyceridemia; Hyperuricemia; Kidney; K | 2014 |
[Efficacy studies].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hy | 2014 |
ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesity.
Topics: Adipocytes; Animals; ATP Binding Cassette Transporter, Subfamily D; ATP-Binding Cassette Transporter | 2014 |
Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia.
Topics: Animals; Apolipoprotein A-I; Arginine; C-Reactive Protein; Cardiotonic Agents; Cholesterol, HDL; Dos | 2015 |
PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.
Topics: Adult; Aged; Chemokine CCL5; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypertriglyceri | 2016 |
[Fibrates: their prescription must be restricted].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Prescriptions; Fenofibrate; Fibric Acids; F | 2015 |
A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.
Topics: Clinical Trials as Topic; Female; Fenofibrate; Genetic Markers; Genome-Wide Association Study; Genot | 2016 |
Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Chemotherapy, Adjuvant; Drug Th | 2017 |
Pharmacoeconomic analysis of hypertriglyceridemia treatment at medical institutions.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Cost-Benefit Analysis; Eco | 2008 |
Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Apolipoprotein A-V; Apolipoproteins A; Cross-Sect | 2009 |
Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein A-V; Apolipoprotein C-III; Apolipoproteins; Apolipoprotein | 2009 |
Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.
Topics: Adult; Aged; Bexarotene; Contraindications; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; | 2009 |
Hypertriglyceridemia and its pharmacologic treatment among US adults.
Topics: Adult; Female; Fenofibrate; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; M | 2009 |
The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study.
Topics: Adult; Apolipoprotein A-V; Apolipoproteins A; Dietary Fats; Female; Fenofibrate; Humans; Hypertrigly | 2009 |
Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism.
Topics: Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Hypothyroidism; Male; Middle Aged; | 2009 |
Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis.
Topics: Atorvastatin; Cholesterol; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Drug Therapy, Co | 2009 |
Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha.
Topics: Animals; Apolipoprotein A-V; Apolipoproteins; Atorvastatin; Cell Line, Tumor; Drug Synergism; Fenofi | 2009 |
Severe hypertriglyceridemia and recurrent pancreatitis in a girl with type Ia glycogen storage disease and type III hyperlipoproteinemia.
Topics: Apolipoproteins E; Biopsy; Child, Preschool; Female; Fenofibrate; Glycogen Storage Disease Type I; H | 2009 |
Concerns about heparin therapy for hypertriglyceridemia.
Topics: Atorvastatin; Cholesterol; Chylomicrons; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Dr | 2010 |
Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice.
Topics: Animals; CD36 Antigens; Chylomicrons; Fenofibrate; Hypertriglyceridemia; Intestinal Mucosa; Metaboli | 2010 |
The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diabetes Mellitus; Dyslip | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cholesterol, HDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fen | 2010 |
Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate.
Topics: Adult; Blood Glucose; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Infan | 2011 |
Effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate.
Topics: Animals; Cholesterol; Cyclooctanes; Disease Models, Animal; Dose-Response Relationship, Drug; Fenofi | 2011 |
Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Female; Fenofibrate; Humans; Hypertriglyceridemia; H | 2011 |
Paradoxical decrease in serum high-density lipoprotein cholesterol with Tredaptive® (m/r nicotinic acid 1 g and laropiprant 20 mg).
Topics: Adult; Cholesterol, HDL; Drug Combinations; Drug Substitution; Fenofibrate; Humans; Hypertriglycerid | 2011 |
Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P450 Family 2; Enzyme Repression; Fenofibrate; Hy | 2011 |
[Multiple cutaneous osteomas of the face in a setting of chronic acne].
Topics: Acne Vulgaris; Adult; Anti-Bacterial Agents; Dermatologic Agents; Durapatite; Female; Fenofibrate; H | 2011 |
Use of fenofibrate during the first trimester of unplanned pregnancy in a patient with hypertriglyceridemia.
Topics: Adult; Female; Fenofibrate; Fetal Development; Humans; Hypertriglyceridemia; Hypolipidemic Agents; I | 2012 |
Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia.
Topics: Adult; Aged; Blood Flow Velocity; Chemokine CCL2; Coronary Circulation; Female; Fenofibrate; Homocys | 2013 |
Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra.
Topics: Acitretin; Acrodermatitis; Antirheumatic Agents; Drug Administration Schedule; Drug Resistance, Mult | 2012 |
Severe hypertriglyceridaemia. Treatment with plasmapheresis.
Topics: Acrylic Resins; Combined Modality Therapy; Fenofibrate; Filtration; Fluorobenzenes; Humans; Hydropho | 2012 |
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, | 2013 |
Beyond low-density lipoprotein cholesterol: why, who and when.
Topics: Coronary Disease; Drug Therapy, Combination; Exercise; Fenofibrate; Humans; Hypertriglyceridemia; Hy | 2012 |
Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins E; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Epist | 2012 |
Fenofibrate attenuates impaired ischemic preconditioning-mediated cardioprotection in the fructose-fed hypertriglyceridemic rat heart.
Topics: Animals; Cholesterol; Creatine Kinase, MB Form; Fenofibrate; Fructose; Hypertriglyceridemia; Hypolip | 2013 |
[Usefulness of examination of the cholesterol versus triglyceride ratio for lipoprotein fractions in a patient with marked hyper-triglyceridemia].
Topics: Acute Disease; Adult; Biomarkers; Cholesterol; Fenofibrate; Humans; Hypertriglyceridemia; Lipoprotei | 2002 |
Lipemia retinalis associated with branch retinal vein occlusion.
Topics: Combined Modality Therapy; Diet Therapy; Exercise Therapy; Female; Fenofibrate; Humans; Hyperlipopro | 2003 |
Effect of micronized fenofibrate on vascular endothelial function in patients with hypertriglyceridemia.
Topics: Adult; Endothelium, Vascular; Female; Fenofibrate; Humans; Hypertriglyceridemia; Male; Middle Aged; | 2003 |
Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome.
Topics: Adipose Tissue; Animals; Apolipoprotein C-III; Apolipoproteins C; Disease Models, Animal; DNA-Bindin | 2004 |
Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice.
Topics: Acyl-CoA Oxidase; Adipose Tissue; Animals; Apolipoproteins C; Body Weight; Cholesterol; Dietary Fats | 2004 |
Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy.
Topics: Adult; Female; Fenofibrate; HIV-Associated Lipodystrophy Syndrome; Humans; Hypertriglyceridemia; Mal | 2004 |
Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10?
Topics: Adult; Blood Pressure; Cholesterol; Coenzymes; Creatinine; Diet; Drug Resistance; Fatty Acids, Omega | 2005 |
Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein B-100; Apolipoprotein E3; Apolipoproteins B; | 2005 |
Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
Topics: Adiposity; Animals; Aorta; Coronary Artery Disease; Diet, Atherogenic; Energy Metabolism; Fenofibrat | 2006 |
A novel experimental model of acute hypertriglyceridemia induced by schisandrin B.
Topics: Animals; Cyclooctanes; Disease Models, Animal; Fenofibrate; Hypertriglyceridemia; Hypolipidemic Agen | 2006 |
High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: animal models of acute hypertriglyceridemia.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins B; Biphenyl Compounds; Cholesterol; Disease Models, Ani | 2006 |
Fenofibrate can increase serum creatinine levels in renal insufficiency.
Topics: Contraindications; Creatinine; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Rena | 2006 |
Therapy and clinical trials.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fenofibrate; Humans; H | 2006 |
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Topics: Adult; Aged; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Apolipoproteins E; Atorvas | 2006 |
Hypertriglyceridemia and hepatic steatosis in senescence-accelerated mouse associate to changes in lipid-related gene expression.
Topics: Aging; Analysis of Variance; Animals; Blotting, Western; Fatty Liver; Fenofibrate; Gene Expression R | 2007 |
Elevated serum creatinine levels associated with fenofibrate therapy.
Topics: Chronic Disease; Creatinine; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Kidney | 2008 |
Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Female; Fenofibrate; Follow-Up Studies; Hum | 2009 |
[Relation between hypertriacylglycerolemia and the action of insulin in type 2 diabetes mellitus].
Topics: Adult; Aged; Clofibrate; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypertriglyceridemi | 1994 |
Fenofibrate for hypertriglyceridemia.
Topics: Adipose Tissue; Anticoagulants; Cholesterol, VLDL; Dose-Response Relationship, Drug; Drug Interactio | 1998 |
Effect of low HDL combined with hypertriglyceridemia in coronary artery disease patients on PGI2 biological activity in relation to lipid regulating treatment.
Topics: Coronary Disease; Epoprostenol; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Hyp | 1998 |
Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Fenofibrate; HIV Protease Inh | 2000 |
Resistant hypertriglyceridemia in a patient with high plasma levels of apolipoprotein CII.
Topics: Adult; Apolipoprotein C-II; Apolipoproteins C; Combined Modality Therapy; Drug Resistance; Fenofibra | 2000 |
[Acute hepatitis and drug dermatitis due to fenofibrate (Secalip)].
Topics: Acute Disease; Adult; Alanine Transaminase; Bilirubin; Biopsy; Chemical and Drug Induced Liver Injur | 2001 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Fenofibrate; Fibrinogen; Gemfibrozil; Homocysteine; Humans; Hypertriglyceridemia; Hypolipidemic Agen | 2001 |
Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
Topics: Adult; Aged; Apolipoproteins E; Female; Fenofibrate; Gene Frequency; Genotype; Humans; Hypertriglyce | 2002 |
[Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia].
Topics: Adult; Aged; Fatty Acids; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; L | 2002 |
Treatment of hypertriglyceridemia with fenofibrate, fatty acid composition of plasma and LDL, and their relations to parameters of lipoperoxidation of LDL.
Topics: Adult; Aged; Fatty Acids; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; L | 2002 |
Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration.
Topics: Apolipoproteins C; Fenofibrate; Humans; Hypertriglyceridemia; Kinetics; Male; Propionates | 1989 |
Effects of fenofibrate on lipoprotein metabolism and fatty acid distribution in Zucker rats.
Topics: Animals; Fatty Acids; Fenofibrate; Hypertriglyceridemia; Intubation, Gastrointestinal; Lipoproteins; | 1988 |